

4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide, a Novel Carbonic Anhydrase and Wnt/ β -Catenin Signaling Pathway Dual-Targeting Inhibitor with Potent Activity against Multidrug Resistant Cancer Cells

Domiziana Masci, Michela Puxeddu, Laura Di Magno, Michele D'Ambrosio, Anastasia Parisi, Marianna Nalli, Ruoli Bai, Antonio Coluccia, Pietro Sciò, Viviana Orlando, Sara D'Angelo, Stefano Biagioni, Andrea Urbani, Ernest Hamel, Alessio Nocentini, Serena Filiberti, Marta Turati, Roberto Ronca, Joanna Kopecka, Chiara Riganti, Cinzia Fionda, Rosa Bordone, Giorgia Della Rocca, Gianluca Canettieri,* Claudiu T. Supuran, Romano Silvestri,* and Giuseppe La Regina



Cite This: *J. Med. Chem.* 2023, 66, 14824–14842




Read Online

ACCESS |

Metrics & More

Article Recommendations

Supporting Information



ABSTRACT: We synthesized new pyrrole and indole derivatives as human carbonic anhydrase (hCA) inhibitors with the potential to inhibit the Wnt/ β -catenin signaling pathway. The presence of both N1-(4-sulfonamidophenyl) and 3-(3,4,5-trimethoxyphenyl) substituents was essential for strong hCA inhibitors. The most potent hCA XII inhibitor **15** ($K_i = 6.8$ nM) suppressed the Wnt/ β -catenin signaling pathway and its target genes MYC, Fgf20, and Sall4 and exhibited the typical markers of apoptosis, cleaved poly(ADP-ribose)polymerase, and cleaved caspase-3. Compound **15** showed strong inhibition of viability in a panel of cancer cells, including colorectal cancer and triple-negative breast cancer cells, was effective against the NCI/ADR-RES DOX-resistant cell line, and restored the sensitivity to doxorubicin (DOX) in HT29/DX and MDCK/P-gp cells. Compound **15** is a novel dual-targeting compound with activity against hCA and Wnt/ β -catenin. It thus has a broad targeting spectrum and is an anticancer agent with specific potential in P-glycoprotein overexpressing cell lines.

INTRODUCTION

Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous enzymes that catalyze the reversible hydration of carbon dioxide to produce monohydrogen carbonate and H^+ ions.¹ CAs fall into eight different classes, α - to t -CAs, but only the α -class is found in mammals. Several genetically distinct CA isoforms in the α -class family, including the human CA (hCA) isoforms, have been recognized.^{2,3} They are cytosolic proteins, mitochondrial matrix proteins, transmembrane proteins, or proteins linked by means of glycosylphosphatidylinositol tails to the plasma membrane. The CA isoforms play key roles in many physiological processes, such as pH homeostasis, electrolyte secretion, biosynthesis of several metabolites, signal

transduction, cell differentiation and proliferation, and oncogenesis.^{4,5}

Dysregulated expression and/or abnormal activity of specific CA isoforms cause onset of several pathological conditions.⁶ The cytosolic CAs I and II are isoforms ubiquitously spread throughout the human body. The CA II plays a relevant physiological role and is found highly expressed not only in red

Received: August 3, 2023
Revised: October 11, 2023
Accepted: October 12, 2023
Published: October 30, 2023






Figure 1. Structures 1–21. Compounds: 1, CA inhibitor; 2–5, tubulin polymerization inhibitors; 6, acetazolamide; 7,8: Wnt/ β -catenin modulators; 9: P-gp modulator; and 10–21: planned inhibitors (see Table 1 for R_1 – R_3 substituents).

Table 1. Inhibition Data of Human CA Isoforms I, II, IX, and XII by Compounds 10–21 and Reference Compounds 1 and AAZ^c

compd	R_1	R_2	R_3	K_i (nM) ^{a,b}			
				hCA I	hCA II	hCA IX	hCA XII
10	4-SO ₂ NH ₂	H	H	73.1	57.5	66.0	47.1
11	4-SO ₂ NH ₂	3,4,5-(OCH ₃) ₃	H	95.6	10.2	44.8	11.5
12	3-SO ₂ NH ₂	3,4,5-(OCH ₃) ₃	H	643.8	84.2	34.7	21.3
13	2-SO ₂ NH ₂	3,4,5-(OCH ₃) ₃	H	5837	887.5	228.6	425.4
14	4-SO ₂ NH ₂	H	phenyl	208.9	72.4	38.6	59.4
15	4-SO ₂ NH ₂	3,4,5-(OCH ₃) ₃	phenyl	272.1	33.6	24.1	6.8
16	3-SO ₂ NH ₂	3,4,5-(OCH ₃) ₃	phenyl	1028	186.5	39.1	28.9
17	2-SO ₂ NH ₂	3,4,5-(OCH ₃) ₃	phenyl	>10,000	>10,000	8863	1003
18	4-SO ₂ NH ₂	H		327.8	41.7	31.6	52.0
19	4-SO ₂ NH ₂	3,4,5-(OCH ₃) ₃		446.4	67.8	7.3	16.5
20	3-SO ₂ NH ₂	3,4,5-(OCH ₃) ₃		942.8	228.9	69.0	58.1
21	2-SO ₂ NH ₂	3,4,5-(OCH ₃) ₃		>10,000	>10,000	7751	1193
1				62.0	86.2	9.2	25.4
AAZ ^d				250.0	12.0	25.0	5.7

^aMean from three different assays, by a stopped flow technique. ^bStandard deviations were in the range of ± 5 –10% of the reported K_i values. ^cNo data. ^dAAZ, acetazolamide.

blood cells, the gastrointestinal tract, the lungs, and the kidneys⁷ but also in some types of cancer, such as urothelial carcinoma.⁸ Both isoforms are involved in glaucoma,⁹

epilepsy,¹⁰ and Parkinson's disease.¹¹ The human-membrane-associated CA IX and CA XII enzymes catalyze the hydration of carbon dioxide in the extracellular space. Overexpression of





Figure 2. Structural elements that have been merged to achieve the multitarget activity of 15.

Scheme 1. Synthesis of Sulfonamides 10–13^a




^a(a) NaH, DMF, RT, 50 min, Ar, 90–98%; (b) CuI, Cs₂CO₃, 1,10-phenanthroline, 1,4-dioxane, MW, closed vessel, 210 °C, 200 W, 40 min, 17–61%; (c) TBAF, THF, reflux, 4 h, 70–90%.

both the CA IX and CA XII isoforms is triggered by the hypoxia-inducible factor 1 (HIF-1) in many types of cancer.¹² CA IX is expressed in breast carcinoma, colorectal cancer (CRC), glioblastoma, lung cancer, and cervical squamous cell carcinoma.¹³ High levels of CA XII have been detected in breast cancer,¹⁴ nonsmall cell lung cancer,¹⁵ cervical cancer¹⁶ and gliomas, hemangioblastomas, and meningiomas.¹⁷ A spliced form of CA XII is expressed in brain tumors.¹⁸ Cystic fibrosis-like syndrome and hyponatremia have been associated with a mutation in CA XII.¹⁹ In CRC, the expression of the CA II and CA XII isoforms has been correlated with patient survival, in that higher expression indicated poorer prognosis, and this suggested their potential role as prognostic biomarkers.²⁰

In our previous studies, we synthesized 1,1'-biphenylsulfonamides as potent inhibitors of the hCA isoforms, with nM K_i values.^{21,22} The biphenylsulfonamide 1 showed strong inhibition of hCA isoforms XII and XIV. In this work, we

designed new CA inhibitors by introducing a sulfonamide group at the N1-phenyl of 2–4,^{23–25} whose primary activity was the inhibition of tubulin polymerization, to give compounds 10–21 (Figure 1 and Table 1). Compounds 11, 15, and 19 showed strong inhibition of hCA isoforms I, II, IX, and XII with low nM K_i values (Table 1). These compounds did not significantly inhibit tubulin polymerization, although sulfonamide 5 was reported by Guo²⁶ to inhibit tubulin assembly. Compound 11 did not inhibit tubulin assembly at 20 μM, and 15 and 19 showed only partial inhibition at 20 μM (in this assay, combretastatin A-4 inhibited the tubulin assembly with an IC₅₀ of 0.75 μM) (Table S1, Supporting Information). Overexpression of CA II and β-catenin signaling in urothelial carcinoma was reported by Matsue.²⁷ Although the mechanism was not fully elucidated, the authors hypothesized that CA II may induce epithelial–mesenchymal transition (EMT) upregulating Wnt/β-catenin signaling.²⁸ Reference drug acetazolamide 6 (AAZ) was demonstrated to

Scheme 2. Synthesis of Sulfonamides 14–17 (Top Panel) and 18–21 (Bottom Panel)^a

^a(a) CuI, Cs₂CO₃, 1,10-phenanthroline, 1,4-dioxane, MW, closed vessel, 210 °C, 200 W, 40 min, 24–65%; (b) TBAF, THF, reflux, 4 h, 71–98%.

suppress Wnt/ β -catenin signaling.²⁹ Sulfonamides 7 and 8 were reported by Fang to inhibit Wnt signaling by interfering with both β -catenin/Tcf4 and β -catenin/LEF1 in protein extracts from HCT116 cells.³⁰ The CA XII isoform is required for optimal activity of the P-glycoprotein (P-gp). Increasing CA XII levels at the plasma membrane of P-gp positive cancer cells were found during the acquisition of chemoresistance.³¹ P-gp-mediated chemoresistance is reversed by CA XII inhibitors.³² The 3,4,5-trimethoxybenzoyl moiety of compound 9 was required for modulating P-gp levels.³³

Compound 15, the most potent hCA XII inhibitor within the series, merges key structural features present in compounds 1, 7, 8, and 9, namely, the 4'-benzoyl-(1,1'-biphenyl)-4-sulfonamide of 1, the 4-ureidobenzenesulfonamide of 7 and 8, and the 3,4,5-trimethoxybenzoyl moiety of 15. A summary sketch of the elements that have been merged to achieve the multitarget activity of compound 15 is shown in Figure 2. We were intrigued by the ability of compound 15 to interfere with the Wnt/ β -catenin pathway and to restore the drug sensitivity of P-gp-overexpressing cancer cells. Indeed, 15 inhibited effectively the Wnt/ β -catenin pathway and its target gene MYC, and besides its activity in NCI/ADR-RES cells, restored the sensitivity to doxorubicin (DOX) in HT29/DX and MDCK/P-gp cells. In the HT29/DX model, 15 at 100 nM in combination with DOX decreased the cell viability obtained with DOX alone in these chemosensitive cells.

RESULTS AND DISCUSSION

Chemistry. Sulfonamides 10–13 were prepared as depicted in Scheme 1. 3-Aroylpyrroles 10 and 11 were synthesized starting by reaction of ketones 22 or 23³⁴ with the 2-(trimethylsilyl)ethoxymethyl (SEM) protected 4-bromo-*N,N*-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (24) in the presence of copper(I) iodide, cesium carbonate, and 1,10-phenanthroline under microwave irradiation at 210 °C, 200 W for 40 min to give 4-(3-benzoyl-1*H*-pyrrol-1-yl)-*N,N*-bis((2-(trimethylsilyl)ethoxy)methyl)-benzenesulfonamide (27) or the corresponding 3-(3',4',5'-trimethoxybenzoyl-1*H*-pyrrol-1-yl) derivative (28). Similarly, 29 and 30 were obtained starting from 23 and 3-bromo-*N,N*-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (25) or 2-bromo-*N,N*-bis((2-(trimethylsilyl)ethoxy)methyl)-benzenesulfonamide (26), respectively. Finally, the SEM protecting groups of 27–30 were removed by heating under reflux in tetrahydrofuran (THF) for 4 h in the presence of tetrabutylammonium fluoride (TBAF). The SEM-protected bromophenylsulfonamides 24–26 were obtained by reaction of 4-bromobenzenesulfonamide, or its 2- or 3-bromo counterparts, with trimethylsilyl ethoxymethyl chloride in the presence of sodium hydride in *N,N*-dimethylformamide at room temperature for 50 min under an argon stream (Scheme 1).

Sulfonamides 14–21 were prepared by similar routes, as depicted in Scheme 2. Compounds 14–17 were synthesized starting from 3-aryol-4-phenylpyrroles 31³⁵ and 32³⁴ (Scheme

2, panel A) and 18–21 starting from 3-aryloindoles 37 and 38³⁶ (Scheme 2, panel B).

Biology. *Inhibition of hCA I, hCA II, hCA IX, and hCA XII Isoforms.* Inhibition data of sulfonamides 10–21 against human isoforms CA I, II, IX, and XII were measured by a stopped flow CO₂ hydrase assay.³⁷ The K_i values of 10–21 are presented in Table 1, along with that of the reference drug AAZ, a CA inhibitor medication approved by the FDA to treat glaucoma, idiopathic intracranial hypertension, congestive heart failure, altitude sickness, periodic paralysis and epilepsy,³⁸ and of the previously reported 4,4'-biphenylsulfonamide 1.²¹ Structure–activity relationships (SARs) can be gathered from the K_i inhibition values reported in Table 1. As inhibitors of hCA I, pyrrole derivatives 10 ($K_i = 73.1$ nM) and 11 ($K_i = 95.6$ nM) were more potent than the corresponding 4-phenylpyrroles 14 and 15 and indoles 18 and 19 and were at the same level of the reference 1,1'-biphenylsulfonamide 1 ($K_i = 62.0$ nM). Shifting the sulfonamide moiety from the *para* position in 11 to *meta* or *ortho* position in 12 or 13 resulted in a 6.7- and 61.0-fold reduction in the inhibition of hCA I, respectively. Sulfonamides 11, 15, and 18 yielded hCA II inhibition with K_i values < 50 nM. In particular, compound 11 showed the strongest inhibition of hCA II ($K_i = 10.2$ nM) within the series and was comparable to AAZ ($K_i = 12.0$ nM). Several sulfonamides inhibited hCA IX with $K_i < 50$ nM. Compound 15 ($K_i = 24.1$ nM) was equipotent to AAZ ($K_i = 25.0$ nM). The most potent hCA IX inhibitor 19 ($K_i = 7.3$ nM) was superior to the references 1 ($K_i = 9.2$ nM) and AAZ ($K_i = 25.0$ nM). Sulfonamides, 10–12, 15, 16, and 19, inhibited hCAXII with $K_i < 50$ nM. In all series, the strong inhibition correlated with the presence of the sulfonamide at the *para* position and with the 3,4,5-trimethoxyphenyl group. Pyrrole derivatives 11 ($K_i = 11.5$ nM) and 15 ($K_i = 6.8$ nM) showed the strongest hCA XII inhibition. As inhibitors of hCA XII, 11 and 15 were superior to the reference compound 1, and 15 was comparable to AAZ. A SAR summary of inhibition of hCA I, hCA II, hCA IX, and hCA XII by compounds 10–21 is depicted in Figure 3.




Figure 3. SAR summary of hCA I, hCA II, hCA IX, and hCA XII inhibition by compounds 10–21.

Molecular Modeling on hCA I, hCA II, hCA IX, and hCA XII Isoforms. Docking experiments were performed to gain insights into the molecular details of the binding modes of the reported compounds. Representative structures for each studied hCA isoform were selected from the protein data bank (PDB) server. The compounds were docked by Vina to the catalytic site of the enzymes. Inspection of the proposed docking binding conformations revealed the crucial interaction between the sulfonamide nitrogen atom and the catalytic zinc atom. The position *para*, *meta*, or *ortho* of the sulfonamide at the 1-phenyl ring markedly affected the binding interaction;

the most active compounds all had the sulfonamide at the *para* position. This resulted in its contact involving the zinc atom of the enzyme and the sulfonamide moiety formed an H-bond between an oxygen atom and the Thr199 residue. The phenyl ring bearing the sulfonamide formed hydrophobic interactions with Leu198, a residue that was conserved in all the studied isoforms, and Val121 which became an Ala residue in hCA I. When the sulfonamide group was at the *meta* or *ortho* position, a steric clash resulted in attempting to achieve a proper bond distance from the zinc atom.

Inspection of the binding modes led to the identification of hydrophobic interactions of the central pyrrole or indole ring with Pro202 and Leu198, both of which are conserved in all of the studied isoforms. Other hydrophobic interactions involved residues Leu131 in hCA I, Phe131 in hCA II, Val131, and Ala131 in hCA IX and Ala131 hCA XII. The 3,4,5-trimethoxyphenyl formed hydrophobic interactions with Phe131, Val135, and Leu204 in the case of hCA II and with Val131, Leu135, and Ala204 in the case of hCA IX. For hCA XII, along with the hydrophobic stabilization provided by the trimethoxyphenyl, an H-bond interaction between Ser132 and a methoxy group was observed. In the case of hCA I, the presence of the bulkier Tyr204 residue instead of Leu (hCA II), Ala (hCA IX), or Asn (hCA XII) forced the trimethoxyphenyl moiety into a different binding conformation that caused lower-quality binding. The binding modes provided by the docking experiments were consistent with the biological data and led to the identification of crucial structural requirements for inhibition of the enzyme (Figure 4).

Inhibition of Tubulin Polymerization and Docking in the Colchicine Site. At 20 μ M, compound 11 did not inhibit tubulin assembly, whereas 15 and 19 resulted in partial inhibition. In the same assay, combretastatin A-4 (CSA4) as a reference compound inhibited the assembly reaction with an IC₅₀ of 0.75 μ M and colchicine binding with 99% inhibition. For comparison, 2, the parent compound of 11, inhibited tubulin assembly with an IC₅₀ of 1.5 μ M and colchicine binding by 81%;²³ 3, the parent compound of 15, inhibited tubulin assembly with IC₅₀ of 1.1 μ M and colchicine binding by 66%.²⁴ Docking studies of derivatives 11, 15, and 19 at the colchicine site of the tubulin dimer highlighted that binding modes of 11 and 15 were consistent with those of the previously reported parent compounds 2²³ and 3,²⁴ respectively; however, the sulfonamide group had a negative effect on binding to the colchicine site. Inspection of the docking poses revealed that while the sulfonamide groups of 11, 15, and 19 could fit into a hydrophobic pocket, there were no stabilizing contacts. This may suggest that the desolvation energy cost was not balanced by the binding energy of the sulfonamide moiety.³⁹ For all derivatives, we hypothesized that the binding fitness got worse upon the introduction of the sulfonamide group mainly due to electronic rather than steric reasons (Figure S1, Supporting Information).

Inhibition of Growth of HCT-116, SW480, and SW620 Cancer Cells. Compounds 11, 15, and 19 were evaluated as inhibitors of the growth of the HCT116, SW480, and SW620 colorectal carcinoma cells (Table 2 and Figure S2, Supporting Information). All cell lines are characterized by enhanced activity of the Wnt/ β -catenin pathway due to the CTNNB1 mutated gene present in the HCT116 cells that encodes β -catenin⁴⁰ and mutation in the APC tumor suppressor gene in SW480 and SW620 cells.^{41,42} Compounds 15 and 19 inhibited




Figure 4. Proposed binding mode of derivatives **11** (orange), **15** (magenta), and **19** (cyan). Enzymes are shown as a colored cartoon: hCA I, light blue; hCA II, green; hCA IX, gray; and hCA XII, sand. The zinc atom is depicted as a green sphere; residues involved in interactions are shown as white sticks; H-bonds are depicted as yellow dot lines. For the sake of clarity, amino acid residue numbers refer to hCA I.

Table 2. Inhibition of Growth of HCT-116, SW480, and SW620 Cancer Cells by Compounds **15 and **19**^a**

compd	IC ₅₀ (μM)		
	HCT116 ^b	SW480 ^b	SW620 ^b
15	8.7 ± 1.4	17.7 ± 1.3	23.8 ± 1.4
19	14.9 ± 1.3	37.4 ± 1.4	45.4 ± 1.7
5-FU	8.2 ± 1.5	217.5 ± 1.3	102.6 ± 2.4
15 + 5-FU ^c	17.0 ± 8.0	42.9 ± 1.2	37.3 ± 1.2
19 + 5-FU ^c	14.0 ± 2.1	50.3 ± 1.2	25.8 ± 1.2

^aExperiments were performed in duplicate or triplicate. ^bHuman colorectal carcinoma cells. ^c**15**, **19**, and 5-FU were at the corresponding IC₅₀ concentrations.

the HCT116 cells with IC₅₀'s of 8.7 and 14.9 μM, respectively, compared with 5-fluorouracil (5-FU) (IC₅₀ = 8.2 μM). Both SW480 and SW620 cell lines were less sensitive to **15** and **19** than the HCT116 cells, with IC₅₀ values ranging from 17.7 μM (**15**, SW480 cells) to 45.4 μM (**19**, SW620 cells). However, it should be noted that **15** and **19** were remarkably more potent than 5-FU as inhibitors of both the SW480 and SW620 cell lines. As an inhibitor of the SW480 and SW620 cells, 5-FU yielded IC₅₀'s of 217.5 and 102.6 μM, respectively, and was 27- and 13-fold less effective than that in the HCT116 cells. In drug combination studies, each compound was used at the corresponding IC₅₀ concentration. The combination **15** + 5-FU inhibited the HCT116 cells with an IC₅₀ of 17.0 μM, two-fold higher than **15** as a single agent, while **19** + 5-FU was at the same level as **19** alone. As inhibitors of the SW480 and

SW620 cells, **15** + 5-FU and **19** + 5-FU combinations were superior to 5-FU as a single agent; in the SW620 cells, **19** + 5-FU was 1.8-fold superior than **19** alone.

Inhibition of Growth of MCF-7, NCI/ADR-RES, and OVCAR-8 Cancer Cells. Compounds **11**, **15**, and **19** were evaluated as inhibitors the growth of human nonmetastatic breast cancer epithelial cells (MCF-7), the ovarian tumor cell line 8 (OVCAR-8), and its derived NCI/ADR-RES DOX-resistant cell line that overexpresses P-gp, resulting in the type 1 multidrug-resistance phenotype (Table 3). Compounds **11**,

Table 3. Inhibition of Growth of MCF-7, OVCAR-8, and NCI/ADR-RES Cell Lines by Compounds 11, 15, and 19^a

compd	IC ₅₀ (μM)		
	MCF-7 ^{b,c}	OVCAR-8 ^d	NCI/ADR-RES ^e
11	3.9 ± 0.08	1.9 ± 0.07	2.2 ± 0.5
15	1.9 ± 0.05	1.9 ± 0.07	2.1 ± 0.6
19	3.6 ± 1.0	4.8 ± 0.3	2.1 ± 0.2

^aExperiments were performed in duplicate or triplicate. ^bMCF-7 human nonmetastatic breast cancer epithelial cells. ^cIn this assay, CSA4 as a reference compound yielded IC₅₀ of 15 ± 4 nM. ^dOVCAR-8: ovarian tumor cell line 8. ^eNCI/ADR-RES: DOX-resistant cell line derived from OVCAR-8.

15, and **19** inhibited the MCF-7, OVCAR-8, and NCI/ADR-RES cancer cells with IC₅₀ values ranging from 1.9 μM (**15**, MCF-7 cells; **11** and **15**, NCI/ADR-RES and OVCAR-8 cells) to 4.8 (**19**, OVCAR-8 cells). Compound **15** was almost uniformly active against these three cell lines in the 1.9–2.1 μM range. Noteworthy, compounds **1**, **12**, and **19** were

equipotent as inhibitors of the NCI/ADR-RES DOX-resistant cell line (EC₅₀'s of 2.1–2.2 μM), uniformly more active than the tubulin assembly inhibitor vinorelbine (IC₅₀ = 5.0 ± 1.0 μM) and slightly less potent than microtubule-stabilizing agent paclitaxel (IC₅₀ = 1.5 ± 0.7 μM).⁴³

Inhibition of TNBC Cancer Cells. Chemotherapy is still the standard of care for triple-negative breast cancer (TNBC). Poor prognosis is often ascribed to the emergence of drug resistance to therapeutic agents. In order to evaluate the biological effect of CA inhibitors in TNBC cells, we used MDA-MB 231 and BT-549 cells, which are representative of highly aggressive TNBC subtypes. As shown in Figure 5, Panel A, treatment with compound **15** exerted a potent antiproliferative effect on MDA-MB 231 cells. The effect of **15** was significantly higher as compared with the reference compound SLC-0111, an ureido-substituted benzenesulfonamide small molecule inhibitor of CA IX in Phase 1 trials in patients with advanced solid tumors⁴⁴ (Figure 5, Panel B). Similarly, when tested on BT-549 cells, **15**, significantly impaired cell growth (Figure 5, Panel C) as compared with SLC-0111 (Figure 5, Panel D).

Human Primary T Lymphocytes. Potential toxic effects of compound **15** on healthy cells were evaluated by treating human primary T lymphocytes with **15** at 30 μM or with dimethyl sulfoxide (DMSO) as a control vehicle. After 72 h, the frequency of late apoptotic cells was assayed by staining with annexin V and propidium iodide. Flow cytometry analysis showed that compared to the control vehicle, treatment with 30 μM **15** caused very low-level toxicity on healthy/normal cells with only a 6–8% increase in cell death (Figure 6).




Figure 5. (A) Inhibition of MDA-MB 231 TNBC cell growth by compound **15**. (B) Inhibition of MDA-MB 231 TNBC cell growth by reference compound SLC-0111. (C) Inhibition of BT-549 TNBC cell growth by compound **15**. (D) Inhibition of BT-549 TNBC cell growth by reference compound SLC-0111.




Figure 6. Human primary T cells were treated with **15** at 30 μM or DMSO for 72 h and analyzed for annexin V by flow cytometry. The frequency of annexin V/propidium iodide double positive cells (top right, late phase apoptotic cells) is shown. Data from two different healthy donors (donor A and donor B) are shown.

Detection of Markers of Apoptosis in 15-Treated HCT116 Cells. The inhibitory effect of compound **15** on cell growth could be attributed to the induction of programmed cell death. Detection of cleaved poly(ADP-ribose) polymerase (PARP) by antibodies is considered a prominent marker of apoptosis. The cleavage of PARP-1 during apoptosis produces two terminal fragments: an 89 kDa C-terminal fragment that contains the catalytic domain and a 24 kDa N-terminal fragment containing the DNA-binding domain. Overexpression of the 24 kDa N-terminal fragment inhibits DNA repair and ADP-ribose formation and stimulates apoptosis,⁴⁵ with consequent increase of PARP full-length/cleaved ratio and a darker cleaved band. During apoptosis, caspase-3 is a major cause of proteolysis. Detection of cleaved caspase-3 is also a reliable marker of apoptosis since it allows the quantification of cells that are dying or have died by apoptosis.⁴⁶ Treatment of HCT116 cells with increasing concentrations of compound **15** for 72 h highlighted increments of cleaved PARP and cleaved caspase-3 (Figure 7, and Figures S3 and S4, Supporting Information).




Figure 7. Total and cleaved PARP levels and cleaved caspase-3 levels in HCT116 cells after a 72 h treatment with increasing concentrations of compound **15**.

Inhibition of the Wnt/ β -Catenin Signaling Pathway by 15. We wondered whether the observed inhibitory effect of compound **15** on CRC cell viability could be attributed to its ability to affect Wnt signaling. To this end, we first transfected human embryonic kidney (HEK) 293T cells with a reporter vector (M50 Super 8x TOPFlash) containing eight repeats of TCF/LEF-binding sites, or its negative control containing the mutated TCF/LEF binding sites (M51 Super 8x FOPFlash). After transfection, cells were treated with the GSK3 inhibitor LiCl to activate the Wnt pathway and incubated with increasing concentrations of **15**. As shown in Figure 8, the




Figure 8. HEK-293 cells were transfected with luciferase-based vectors and treated with LiCl (50 mM) together with increasing concentrations of compound **15**. Cells were harvested 24 h post-treatment and assayed for luciferase activity. Inhibition levels calculated as the luciferase/renilla ratio of the treated samples vs the luciferase/renilla ratio of the untreated (control) samples. Data are represented as the mean \pm SD of three independent experiments, each performed in triplicate. * $p < 0.05$ and ** $p < 0.01$, as determined by analysis of variance (ANOVA).

compound caused a significant and dose-dependent inhibition of TOP reporter activity but did not significantly prevent the activity of the FOP reporter, indicating the specificity of the effect.

Treatment of HCT116 CRC cells with increasing concentrations of **15** resulted in a marked reduction of β -catenin and of its target gene MYC (Figure 9, left panel). Furthermore, the compound significantly reduced the expression of two additional Wnt target genes,⁴⁷ *Fgf20* and *Sal4* (Figure 9, right panel). Together, these data support the hypothesis that **15** exerts its inhibitory effect on the CRC cell viability and growth by preventing the activation of Wnt/ β -catenin signaling.

Inhibition of P-gp by 15. To test the efficacy of compound **15**, we chose the DOX-sensitive colon cancer HT29 cells, a cell line expressing low levels of P-gp, and its resistant counterpart, the cell line HT29/DX, selected stepwise in media with increasing concentrations of DOX resulting in expression of a high level of P-gp.⁴⁸ As a cancer model, the HT29 and HT29/DX pair has been extensively used and characterized for DOX resistance and pharmacological efficacy by our group,^{49,50} and the cell line pair has important translational potential. However, HT29/DX cells also express other ABC transporters




Figure 9. Left panel. HCT116 cells were treated with LiCl (50 mM) and compound 15 at the indicated concentrations for 24 h. β -Catenin and c-Myc levels were analyzed by Western blot. Actin was used as a loading control. Right panel. *Fgf20* or *Sall4* mRNA levels were measured by qPCR and normalized to the expression of β -actin mRNA and expressed as a fold change relative to the control sample. Results represent the mean \pm SD of three independent experiments, each performed in triplicate. *** p < 0.001, as determined by the t -test.




Figure 10. P-gp ATPase activity, measured spectrophotometrically on the protein immune-purified from HT29/DX cells (A) or MDCK/P-gp (B) cells, treated 3 h without (“0”) or with compound 15 at 1, 10, or 100 nM. H. Data are means \pm SD (n = 3). * p < 0.05 and *** p < 0.001: vs untreated (“0”) cells.




Figure 11. Viability of HT29 and HT29/DX (A), MDCK and MDCK/P-gp (B) cells, incubated with fresh medium (ctrl), 5 μ M DOX (dox), alone or coincubated with 1, 10, or 100 nM of 15 for 72 h, measured with a spectrophotometric assay. Data are means \pm SD (n = 4). *** p < 0.001: versus untreated HT29 or MDCK cells (“ctrl”); $^{\circ}$ p < 0.001: versus untreated HT29/DX or MDCK/P-gp cells (“ctrl”); and ### p < 0.001: versus dox-treated HT29/DX or MDCK/P-gp cells.

including MRP1, MRP2, MRP3, MRP5, and BCRP.⁴⁸ Hence, to better elucidate the effect that the compound under study here has on P-gp, we also included the canine kidney MDCK cell line, devoid of any transporter, and the MDCK/P-gp cell line, overexpressing human P-gp only,⁵¹ as an internal control. In a preliminary experiment, we measured the cytotoxicity of compound 15 alone. Compound 15 reduced cell viability in the four cell lines, suggesting that there was not a cell-dependent effect or a different behavior between DOX-sensitive and resistant cell lines. The viability was >75% with 1–100 nM 15 (Figure S5, Supporting Information). We worked at 1, 10, and 100 nM concentrations in the subsequent experiments to avoid any bias related to the intrinsic cytotoxicity induced by the compound.

To evaluate the impact as chemosensitizer agents, we first measured the intracellular accumulation of DOX, a typical substrate of P-gp.⁵² As expected, HT29 had a basally higher accumulation of the drug compared to the resistant counterpart HT29/DX cells. Similarly, the intracellular amount of

DOX in MDCK cells was significantly higher than that in MDCK/P-gp cells (Figure S6, Supporting Information). Compound 15 had no effects on the amount of DOX retained within HT29 cells, nor in MDCK/P-gp cells, where 15 did not change the intracellular amount of the drug. DOX was basally higher in MDCK/P-gp cells than that in HT29 cells: this difference can be explained because HT29 cells also have other ABC transporters (as MRP1) that, although expressed at low levels, can efflux DOX, while MDCK cells lack other transporters. Differently from what we observed in sensitive cells, 15 induced a strong dose-dependent increase in the DOX accumulation in HT29/DX cells, reaching the same level of intracellular drug detected in sensitive HT29 cells when used at 100 nM. This stronger increase in resistant cells is likely due to their higher levels of the ABC transporters that are the putative targets of compound 15. Indeed, the higher the level of the transporters, the higher the inhibition achieved by the compounds and greater the increase on DOX retention. Part of the effect of 15 is mediated by the inhibition of P-gp, as

Table 4. Drug-like Properties of Compound 15

comp	Log P^a	MW ^b	Log Sw ^c	tPSA ^d	HBA ^e	HBD ^f	rot ^g	Lipinski ^h	Veber ⁱ
15	3.77	492.54	-5.23	118.23	7	1	8	0	0

^aLogarithm of the partition coefficient between *n*-octanol and water computed by the XLOGP3 method. ^bMolecular weight. ^cLogSw represents the logarithm of compound water solubility computed by the ESOL method. Log Sw values predicted compounds likely to be >-10: insoluble, >-6: poorly soluble, >-4: moderately soluble, >-2: soluble, and >0: high soluble. ^dMolecular polar surface area, this parameter has been shown to correlate with human intestinal absorption (<140 Å²). ^eNumber H-bond acceptors. ^fNumber H-bond donors. ^gNumber of rotatable bonds. ^hViolation of the Lipinski rule of five (MW < 500; log P < 5; HBD ≤ 10; HBA ≤ 5). ⁱVeber's rule matching (Rot <10 and tPSA < 140 Å²).

indicated by its efficacy in increasing DOX accumulation in MDCK/P-gp cells, where no other transporters than P-gp are present. In this model, also at the highest concentration (100 nM), the compound was not able to fully restore the accumulation of the drug to the intracellular level of MDCK cells, which were devoid of P-gp. This result can be explained at least by following reasons: (1) the higher catalytic efficiency of the protein in MDCK/P-gp and HT29/DX cells (Figure 10) and (2) the possible targeting of other ABC transporters, present in HT29/DX cells but not in MDCK/P-gp cells.

In determining DOX resistance,⁵² we next investigated if 15 was able to inhibit the catalytic cycle of this transporter. We immunopurified the protein from HT29/DX and MDCK/P-gp cell lines, and we measured the rate of ATP hydrolysis, a step necessary to efflux DOX and considered an index of P-gp activity (Table S2, Supporting Information).⁵³ As shown in Figure 10, P-gp extracted from MDCK/P-gp cells was more active than the protein extracted from the HT29/DX cells. However, in both cell lines, compound 15 reduced P-gp activity, starting at 10 nM concentration. This result suggests that the compound acts as P-gp inhibitors.

Finally, we tested the potential of compound 15 to reverse resistance to DOX in terms of cytotoxicity, by measuring cell viability in cells coincubated with both the compound and 5 μM DOX, a concentration already used to discriminate sensitive and resistant cells.⁵⁴ Also, in our experimental setting, DOX reduced the viability of sensitive HT29 and MDCK cells below 30%, but it did not affect the viability in resistant HT29/DX and MDCK/P-gp cells (Figure 11). In HT29 and MDCK cells, 15 did not further reduce cell viability compared with DOX alone, consistent with the absence of a significant increase in intracellular retention of the drug. By contrast, in HT29/DX and MDCK/P-gp cells, compound 15 decreased cell viability in a dose-dependent manner, restoring the sensitivity to DOX. Particularly, in the HT29/DX model, the combination of DOX plus 15 at 100 nM produced the same decrease in cell viability achieved by DOX alone in the respective chemosensitive cells, confirming that this setting fully overcame the resistance to DOX.

Drug-like Properties of Compound 15. Representative drug-like properties of compound 15 were calculated on the SwissADME website. There were no violations of the Lipinski⁵⁵ and Veber⁵⁶ rules; compound 15 was predicted to have good bioavailability after oral administration (Table 4 and Figure 12).

CONCLUSIONS

We synthesized new pyrrole and indole CA inhibitors 10–21 by modulating the scaffold of previously reported tubulin polymerization inhibitors 2–4.^{21,22} Derivatives bearing the sulfonamide at the *para* position of the N1-phenyl ring showed strong inhibition of the hCA isoforms I, II, IX, and XII with K_i values at nanomolar concentrations. Compounds 11, 15, and




Figure 12. Radar plot of drug-like properties of compound 15. The light green colored zone represents the suitable physicochemical space for oral bioavailability. $-1 < \text{Log } P < 5$; $150 < \text{MW} < 500$; $20 \text{ \AA}^2 < \text{tPSA} < 140 \text{ \AA}^2$; $-10 < \text{Log Sw} < 0$; $0 < \text{HB D} + \text{A} < 10$; and $0 < \text{RotBonds} < 10$. The red line represents values for derivative 15.

19 characterized by the presence of both sulfonamidophenyl and 3,4,5-trimethoxyphenyl substituents at positions 1 and 3, respectively, of the heterocycle were the strongest hCA inhibitors within the series. In particular, 11 inhibited the hCA II and hCA IX isoforms with K_i values of 10.2 and 11.5 nM, respectively; 15 inhibited the hCA XII with K_i of 6.8 nM; and 19 inhibited the hCA IX with K_i of 7.3 nM. Conversely, 11, 15, and 19 had limited ability to inhibit tubulin polymerization: at 20 μM, 15 and 19 produced only partial inhibition of tubulin assembly, while CSA4 inhibited assembly by over 50% at less than 1 μM. The docking poses of compounds 11, 15, and 19 in the binding sites of the four hCA isoforms were consistent with the observed K_i values. On the other hand, the docking poses of 11, 15, and 19 into the colchicine site of tubulin revealed that the sulfonamide group did not form stabilizing contacts, suggesting that the desolvation energy cost was not balanced by the binding energy.

As inhibitors of the HCT116 cells, compounds 15 and 19 were worthy of comparison with 5-FU, and they were remarkably more potent than 5-FU as inhibitors of the SW480 and SW620 cell lines. Compounds 11, 15, and 19 inhibited the MCF-7 and OVCAR-8 cell lines with IC_{50} values in the single digit micromolar range and, notably, were almost equipotent against the NCI/ADR-RES DOX-resistant cell line. Compound 15 potently inhibited MDA-MB 231 and BT-549 TNBC cells and was superior to the reference compound SLC-0111.

Compound **15** caused significant suppression of the Wnt/ β -catenin signaling pathway, as indicated by inhibition of TOP reporter activity, and its target gene MYC, and significantly reduced the expression of the Wnt target genes *Fgf20* and *Sal4*. Compound **15** induced apoptotic programmed cell death, as demonstrated by the increase of apoptotic markers cleaved PARP and cleaved Caspase-3. Compound **15** restored the sensitivity to DOX in HT29/DX and MDCK/P-gp cells. In the HT29/DX model, **15** at 100 nM in combination with DOX decreased the cell viability achieved by DOX alone in the respective chemosensitive cells.

In summary, we describe the synthesis of new pyrrole and indole derivatives as hCA inhibitors with K_i values in the nanomolar range. Compound **15**, the most potent hCA XII inhibitor with $K_i = 6.8$ nM, caused significant suppression of the Wnt/ β -catenin signaling pathway and induced apoptotic cell death in HCT116 cells. Compound **15** restored the sensitivity to DOX in HT29/DX and MDCK/P-gp cells. As a cell growth inhibitor, **15** was equipotent to 5-FU in HCT116 cells and remarkably more potent in the SW480 and SW620 cell lines and inhibited the NCI/ADR-RES DOX-resistant cell line. Against the MDA-MB 231 and BT-549 TNBC cells, **15** was superior to reference compound SLC-0111. Together, these results highlight compound **15** as a novel hCA/ β -catenin pathway dual-targeting broad spectrum anticancer agent with a specific potential to restore sensitivity to P-gp expressing cell lines. These findings highlight **15** as a lead compound of a novel class of dual-targeting broad spectrum anticancer agents and will prompt additional studies to explore its potential for the treatment of cancer.

EXPERIMENTAL SECTION

Chemistry. All reagents and solvents were handled according to the material safety data sheet of the supplier and used as purchased without further purification. Organic solutions were dried over anhydrous sodium sulfate. Evaporation of solvents was carried out on a Büchi Rotavapor R-210 equipped with a Büchi V-850 vacuum controller and a Büchi V-700 vacuum pump. Column chromatography was performed on columns packed with silica gel from the Macherey–Nagel (70–230 mesh). Silica gel thin-layer chromatography (TLC) cards from Macherey–Nagel (silica gel-precoated aluminum cards with a fluorescent indicator visualizable at 254 nm) were used for TLC. Developed plates were visualized with a Spectroline ENF 260C/FE UV apparatus. Melting points (mp) were determined on a Stuart Scientific SMP1 apparatus and are uncorrected. Infrared (IR) spectra were recorded on a PerkinElmer Spectrum 100 FT-IR spectrophotometer equipped with a universal attenuated total reflectance accessory, and IR data were acquired and processed by PerkinElmer Spectrum 10.03.00.0069 software. Band position and absorption ranges are given in cm^{-1} . Proton nuclear magnetic resonance (^1H NMR) spectra were recorded with a Bruker Avance (400 MHz) spectrometer in the indicated solvent, and the corresponding fid files were processed with MestreLab Research SL MestreNova 6.2.1–769 software. Carbon-13 nuclear magnetic resonance (^{13}C NMR) spectra were recorded with a Bruker AVANCE (100 MHz) spectrometer in the indicated solvent, and the corresponding FID files were processed by MestreLab Research SL MestreNova 6.2.1–769 software. Chemical shifts of ^1H and ^{13}C NMR are expressed in δ units (ppm) from tetramethylsilane.

Compound purity was checked by high-pressure liquid chromatography (HPLC). Purity of tested compounds was found to be >95%. The HPLC system used (Thermo Fisher Scientific Inc. Dionex UltiMate 3000) consisted of an SR-3000 solvent rack, an LPG-3400SD quaternary analytical pump, a TCC-3000SD column compartment, a DAD-3000 diode array detector, and an analytical manual injection valve with a 20 μL loop. Samples were dissolved in

acetonitrile (1 mg/mL). HPLC analysis was performed by using a Thermo Fisher Scientific Inc. Acclaim 120 C18 column (5 μm , 4.6 mm \times 250 mm), at 25 ± 1 °C with an appropriate solvent gradient (acetonitrile/water), flow rate of 1.0 mL/min, and signal detector at 206, 230, 254, and 365 nm were used. Chromatographic data were acquired and processed by Thermo Fisher Scientific Inc. Chromeleon 6.80 SR15 Build 4656 software. UHPLC analysis was carried out on an Accela System Thermo Fisher Scientific (San Jose, CA) which consisted of an Accela 1250 Pump, an Accela autosampler, and an Accela PDA photodiode array detector. Chromatographic data were collected and processed using Thermo Xcalibur Chromatography Manager software, version 1.0. A guard cartridge system (SecurityGuard Ultra UHPLC) has been connected to an analytical column Kinetex 2.6 μm EVO C18 100 \AA 100 \times 3.0 mm (L. \times I.D.), both from Phenomenex, Torrance, CA, USA. All analyses were performed at 30 °C, and the mobile phase was filtered through 0.2 μm Omnipore filters (Merck Millipore, Darmstadt, Germany). The mobile phase was delivered at a total flow rate of 0.6 mL/min. The analyses were carried out in the elution gradient. Specific mobile phase and gradient are reported for each compound in captions. Each analysis was performed in triplicate (Figures S7–S9 and Table S3, Supporting Information). Materials: Acetonitrile (HPLC gradient grade), methanol (HPLC gradient grade), water (HPLC gradient grade), and trifluoroacetic acid (HPLC grade) were purchased from Sigma-Aldrich (St. Louis, MO).

General Procedure for the Preparation of Compounds 10–21. Example: 4-(3-Benzoyl-1H-pyrrol-1-yl)benzenesulfonamide (**10**). Compound **27** (191 mg, 0.325 mmol) was dissolved in anhydrous THF (5 mL). TBAF solution 1.0 M in THF (1.12 mL) was added dropwise, and then, the mixture was heated under reflux or 4 h. After being cooled, the mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried on anhydrous sodium sulfate, and filtered. Evaporation of the solvent gave a residue that was purified by silica gel column chromatography (Hex/AcOEt, 1:1) to give **10** (74 mg, 70%), mp 204–206 °C (from ethanol). ^1H NMR (DMSO- d_6 , 400 MHz): δ 6.78 (s, 1H), 7.46 (s, 2H), 7.50–7.55 (m, 3H), 7.59–7.62 (m, 1H), 7.80–7.84 (t, $J = 8$ Hz, 4H), 7.90–7.94 (t, $J = 8$ Hz, 3H) ppm. ^{13}C NMR (DMSO- d_6 , 100 MHz): δ 113.11, 121.19, 122.37, 126.44, 126.59, 128.19, 129.34, 132.83, 139.33, 141.89, 142.24, 190.62 ppm. IR: ν 1162, 1640, 2981 cm^{-1} .

4-(3-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide (**11**). It was synthesized as **10** starting from **28**. Yield 88%, mp 171–174 °C (from ethanol). ^1H NMR (DMSO- d_6): δ 3.80 (d, $J = 9.2$ Hz, 6H), 3.87 (s, 3H), 7.10 (br s, disappeared after treatment with D_2O , 2H), 7.19–7.24 (m, 2H), 7.25–7.35 (m, 3H), 7.60 (d, $J = 8.5$ Hz, 2H), 7.62 (d, $J = 2.4$ Hz, 1H), 8.04 ppm (d, $J = 8.5$ Hz, 2H). ^{13}C NMR (DMSO- d_6 , 100 MHz): δ 56.45, 60.56, 106.72, 112.87, 120.80, 121.96, 126.20, 126.30, 127.79, 134.63, 141.15, 141.63, 142.28, 153.14, 188.70 ppm. IR ν 1463 and 2922 cm^{-1} .

3-(3-(3,4,5-Trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide (**12**). It was synthesized as **10** starting from **29**. Yield 90%, mp 169–171 °C (from ethanol). ^1H NMR (DMSO- d_6 , 400 MHz): δ 3.77 (s, 3H), 3.86 (s, 6H), 6.86 (s, 1H), 7.15 (s, 2H), 7.45 (s, 2H), 7.58–7.59 (m, 1H), 7.69–7.73 (t, $J = 8$ Hz, 1H), 7.77–7.79 (d, $J = 8$ Hz, 1H), 7.98–8.00 (d, $J = 8$ Hz, 1H), 8.08–8.10 (d, $J = 8$ Hz, 2H) ppm. ^{13}C NMR (DMSO- d_6 , 100 MHz): δ 56.00, 66.11, 106.31, 112.36, 117.41, 121.49, 123.38, 123.61, 125.70, 125.74, 130.68, 134.21, 139.24, 140.75, 145.61, 152.68, 188.21 ppm. IR: ν 1641 and 2982 cm^{-1} .

2-(3-(3,4,5-Trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide (**13**). It was synthesized as **10** starting from **30**. Yield 88%, mp 64–66 °C (from ethanol). ^1H NMR (DMSO- d_6 , 400 MHz): δ 3.73 (s, 3H), 3.85 (s, 6H), 6.73–6.74 (m, 1H), 7.10–7.11 (m, 1H), 7.15 (s, 2H), 7.51–7.53 (d, $J = 8$ Hz, 1H), 7.61–7.75 (m, 5H), 8.06–8.08 (d, $J = 8$ Hz, 1H) ppm. ^{13}C NMR (DMSO- d_6 , 100 MHz): δ 55.99, 60.09, 106.21, 110.15, 123.94, 125.60, 128.20, 128.95, 129.64, 131.08, 134.69, 136.63, 139.45, 140.53, 152.63, 189.30 ppm. IR: ν 1644 and 2985 cm^{-1} .

4-(3-Benzoyl-4-phenyl-1H-pyrrol-1-yl)benzenesulfonamide (14). It was synthesized as **10** starting from **33**. Yield 98%, mp 211–214 °C (from ethanol). ¹H NMR (DMSO-*d*₆, 400 MHz): δ 7.21–7.24 (t, *J* = 8 Hz, 1H), 7.28–7.32 (t, *J* = 8 Hz, 2H), 7.41–7.44 (d, *J* = 12 Hz, 4H), 7.47–7.51 (t, *J* = 8 Hz, 2H), 7.59–7.63 (t, *J* = 8 Hz, 1H), 7.86–7.87 (m, 3H), 7.91–7.94 (m, 3H), 7.98–8.00 (d, *J* = 8 Hz, 2H) ppm. ¹³C NMR (DMSO-*d*₆, 100 MHz): δ 120.14, 120.25, 123.38, 126.39, 126.78, 127.33, 127.95, 128.01, 128.28, 128.41, 129.35, 132.29, 133.95, 138.84, 140.94, 141.77, 190.25 ppm. IR: ν 1631 and 3218 cm⁻¹.

4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide (15). It was synthesized as **10** starting from **34**. Yield 80%, mp 223–225 °C (from ethanol). ¹H NMR (DMSO-*d*₆): δ 3.78 (s, 3H), 3.84 (s, 6H), 7.19 (br s, disappeared after treatment with D₂O, 2H), 7.25–7.26 (m, 1H), 7.29–7.37 (m, 2H), 7.49 (m, 4H), 7.93–7.99 (m, 3H), 8.06–8.09 (m, 2H), 8.13 ppm (d, *J* = 2.4 Hz, 1H). ¹³C NMR (DMSO-*d*₆, 100 MHz): δ 55.91, 60.08, 106.98, 119.99, 120.07, 123.44, 126.35, 126.39, 127.31, 127.95, 127.98, 128.24, 133.74, 134.03, 140.93, 141.14, 141.65, 152.48, 189.04 ppm. IR ν 1463 and 2922 cm⁻¹.

3-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide (16). It was synthesized as **10** starting from **35**. Yield 71%, mp 114–116 °C (from ethanol). ¹H NMR (DMSO-*d*₆, 400 MHz): δ 3.73 (s, 3H), 3.78 (s, 6H), 7.14 (s, 2H), 7.20–7.24 (t, *J* = 8 Hz, 1H), 7.28–7.32 (t, *J* = 8 Hz, 2H), 7.40–7.42 (d, *J* = 8 Hz, 2H), 7.45 (s, 2H), 7.70–7.74 (t, *J* = 8 Hz, 1H), 7.78–7.80 (d, *J* = 8 Hz, 1H), 7.81 (s, 1H), 8.01 (s, 1H), 8.04–8.06 (d, *J* = 8 Hz, 1H), 8.18 (s, 1H) ppm. ¹³C NMR (DMSO-*d*₆, 100 MHz): δ 55.92, 60.09, 107.03, 117.10, 120.04, 123.24, 126.37, 127.94, 128.97, 130.64, 133.83, 134.04, 139.02, 141.18, 145.64, 152.49, 189.05 ppm. IR: ν 1164 and 3220 cm⁻¹.

2-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide (17). It was synthesized as **10** starting from **36**. Yield 80% as an oil. ¹H NMR (DMSO-*d*₆, 400 MHz): δ 3.73 (s, 3H), 3.83 (s, 6H), 7.20–7.23 (m, 3H), 7.28–7.32 (m, 3H), 7.42–7.44 (d, *J* = 8 Hz, 2H), 7.52–7.53 (d, *J* = 4 Hz, 1H), 7.62–7.64 (d, *J* = 8 Hz, 1H), 7.67–7.71 (t, *J* = 8 Hz, 3H), 7.74–7.77 (t, *J* = 8 Hz, 1H), 8.07–8.09 (d, *J* = 8 Hz, 1H) ppm. ¹³C NMR (DMSO-*d*₆, 100 MHz): δ 55.99, 60.09, 107.21, 110.25, 119.12, 120.33, 122.94, 125.80, 126.78, 128.40, 128.95, 130.64, 131.08, 134.96, 136.53, 139.51, 141.53, 150.63, 190.30 ppm. IR: ν 1635 and 3222 cm⁻¹.

4-(3-Benzoyl-1H-indol-1-yl)benzenesulfonamide (18). It was synthesized as **10** starting from **39**. Yield 82%, mp 249–252 °C (from ethanol). ¹H NMR (DMSO-*d*₆, 400 MHz): δ 7.39–7.41 (m, 2H), 7.54–7.58 (m, 4H), 7.62–7.67 (m, 2H), 7.91–7.96 (t, *J* = 12 Hz, 3H), 8.03–8.05 (d, *J* = 8 Hz, 2H), 8.24 (s, 1H), 8.38–8.40 (m, 1H) ppm. ¹³C NMR (DMSO-*d*₆, 100 MHz): δ 111.20, 116.45, 122.23, 123.39, 124.59, 125.18, 127.46, 128.66, 128.83, 131.75, 136.05, 137.30, 139.76, 140.32, 143.09, 190.06 ppm. IR: ν 1630 and 3294 cm⁻¹.

4-(3-(3,4,5-Trimethoxybenzoyl)-1H-indol-1-yl)benzenesulfonamide (19). It was synthesized as **10** starting from **40**. Yield 80%, mp 127–130 °C (from ethanol). ¹H NMR (DMSO-*d*₆, 400 MHz): δ 3.77 (s, 3H), 3.87 (s, 6H), 7.21 (br s, disappeared after treatment with D₂O, 2H), 7.38–7.43 (m, 2H), 7.55 (s, 2H), 7.66–7.71 (m, 1H), 7.93–7.95 (m, 2H), 8.02–8.06 (m, 2H), 8.36–8.40 (m, 1H) and 8.42 (s, 1H) ppm. ¹³C NMR (DMSO-*d*₆, 100 MHz): δ 56.54, 60.56, 106.80, 111.59, 116.88, 122.60, 123.68, 124.90, 125.62, 127.82, 128.00, 135.50, 136.50, 137.51, 140.73, 140.97, 143.41, 153.19, 189.50 ppm. IR: ν 1463 and 2922 cm⁻¹.

3-(3-(3,4,5-Trimethoxybenzoyl)-1H-indol-1-yl)benzenesulfonamide (20). It was synthesized as **10** starting from **41**. Yield 71%, mp 224–226 °C (from ethanol). ¹H NMR (DMSO-*d*₆): δ 3.77 (s, 3H), 3.86 (s, 6H), 7.21 (s, 2H), 7.39–7.42 (m, 2H), 7.53 (s, 2H), 7.62–7.64 (m, 1H), 7.81–7.85 (t, *J* = 8.0 Hz, 1H), 7.92–7.97 (m, 2H), 8.09 (s, 1H), 8.36–8.38 (m, 2H) ppm. ¹³C NMR (DMSO-*d*₆, 100 MHz): δ 56.12, 60.13, 106.41, 110.87, 116.35, 121.72, 123.23, 124.71, 127.43, 128.25, 130.95, 135.09, 136.15, 137.12, 138.02, 140.57, 145.47, 152.75, 190.06 ppm. IR: ν 1632 and 3298 cm⁻¹.

2-(3-(3,4,5-Trimethoxybenzoyl)-1H-indol-1-yl)benzenesulfonamide (21). It was synthesized as **10** starting from **42**. Yield 79%, mp 239–241 °C (from ethanol). ¹H NMR (DMSO-*d*₆, 400 MHz): δ 3.74 (s, 3H), 3.86 (s, 6H), 7.00–7.02 (d, *J* = 8 Hz, 1H), 7.20 (s, 2H), 7.25–7.29 (t, *J* = 8 Hz, 1H), 7.31–7.35 (t, *J* = 8 Hz, 1H), 7.58–7.60 (m, 1H), 7.65 (s, 2H), 7.78–7.83 (m, 2H), 8.09 (s, 1H), 8.15–8.18 (m, 1H), 8.32–8.34 (d, *J* = 8 Hz, 1H) ppm. ¹³C NMR (DMSO-*d*₆, 100 MHz): δ 56.02, 60.10, 106.21, 111.24, 115.15, 121.66, 122.53, 123.81, 126.49, 128.50, 129.81, 130.96, 133.22, 134.27, 135.36, 138.80, 140.11, 140.36, 141.20, 152.70, 189.09 ppm. IR: ν 1167 and 3263 cm⁻¹.

General Procedure for the Preparation of Compounds 27–30, 33–36, and 39–42. Example: **4-(3-benzoyl-1H-pyrrol-1-yl)-N,N-bis((2-trimethylsilyloxy)methyl)benzenesulfonamide (27).** An overdried tube was charged at room temperature with **22** (82 mg, 0.479 mmol), **24** (285.45 mg, 0.575 mmol), CuI (45.71 mg, 0.24 mmol), Cs₂CO₃ (234 mg, 0.718 mmol), and 1,10-phenanthroline (8.64 mg, 0.048) in dioxane (6 mL). The mixture was placed into the microwave cavity (close vessel mode, PMAX 200 PSI). Microwave irradiation of 50 W was used at first, then rose up to 200 W. The temperature was ramped from 25 to 210 °C. Once it was reached, taking around 7 min, the mixture was held at this temperature for 40 min. After cooling, the mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried on anhydrous sodium sulfate and filtered. Removal of the solvent gave a residue that was purified by silica gel column chromatography (Cyhex/AcOEt, 8:2) to give **27** (140 mg, 50%) as an oil. ¹H NMR (CDCl₃, 400 MHz): δ 0.04 (s, 18H), 0.82–0.86 (t, *J* = 8 Hz, 4H), 3.47–3.51 (t, *J* = 8 Hz, 4H), 4.78 (s, 4H), 6.90–6.91 (m, 1H), 7.15–7.16 (m, 1H), 7.46–7.56 (m, 5H), 7.64 (s, 1H), 7.86–7.88 (d, *J* = 8 Hz, 2H), 7.99–8.01 (d, *J* = 8 Hz, 2H) ppm. IR: ν 1464 cm⁻¹.

4-(3-(3,4,5-Trimethoxybenzoyl)-1H-pyrrol-1-yl)-N,N-bis((2-trimethylsilyloxy)methyl)benzenesulfonamide (28). It was synthesized as **27** starting from **23** and **24**. Yield 58% as an oil. ¹H NMR (DMSO-*d*₆, 400 MHz): δ 0.00 (s, 18H), 0.81–0.86 (m, 4H), 3.46 (m, 4H), 3.85 (s, 3H), 3.94 (s, 6H), 4.84 (s, 4H), 6.94 (m, 1H), 7.21 (s, 2H), 7.76–7.78 (m, 1H), 8.02–8.05 (m, 2H), 8.08–8.10 (m, 2H) and 8.25–8.26 ppm (m, 1H). IR: ν 1463 and 2922 cm⁻¹.

3-(3-(3,4,5-Trimethoxybenzoyl)-1H-pyrrol-1-yl)-N,N-bis((2-trimethylsilyloxy)methyl)benzenesulfonamide (29). It was synthesized as **27** starting from **23** and **25**. Yield 58% as an oil. ¹H NMR (DMSO-*d*₆, 400 MHz): δ 0.11 (s, 18H), 0.68–0.72 (t, *J* = 8 Hz, 4H), 3.35–3.40 (t, *J* = 8 Hz, 4H), 3.77 (s, 3H), 3.86 (s, 6H), 4.78 (s, 4H), 6.83 (s, 1H), 7.15 (s, 2H), 7.63 (s, 1H), 7.69–7.73 (t, *J* = 8 Hz, 1H), 7.81–7.83 (d, *J* = 8 Hz, 1H), 8.05–8.07 (d, *J* = 8 Hz, 1H), 8.11 (s, 1H), 8.15 (s, 1H) ppm. IR: ν 1464 and 2919 cm⁻¹.

2-(3-(3,4,5-Trimethoxybenzoyl)-1H-pyrrol-1-yl)-N,N-bis((2-trimethylsilyloxy)methyl)benzenesulfonamide (30). It was synthesized as **27** starting from **23** and **26**. Yield 24% as an oil. ¹H NMR (DMSO-*d*₆, 400 MHz): δ 0.09 (s, 18H), 0.65–0.69 (t, *J* = 8 Hz, 4H), 3.28–3.32 (t, *J* = 8 Hz, 4H), 3.71 (s, 3H), 3.84 (s, 6H), 4.40 (s, 4H), 6.78 (s, 1H), 7.00–7.02 (t, *J* = 4 Hz, 1H), 7.15 (s, 2H), 7.55–7.57 (d, *J* = 8 Hz, 1H), 7.60 (s, 1H), 7.70–7.74 (t, *J* = 8 Hz, 1H), 7.80–7.83 (t, *J* = 4 Hz, 1H), 8.10–8.12 (d, *J* = 8 Hz, 1H) ppm. IR: ν 1464 and 2919 cm⁻¹.

4-(3-Benzoyl-4-phenyl-1H-pyrrol-1-yl)-N,N-bis((2-trimethylsilyloxy)methyl)benzenesulfonamide (33). It was synthesized as **27** starting from **31** and **24**. Yield 33% as an oil. ¹H NMR (DMSO-*d*₆, 400 MHz): δ 0.08 (s, 18H), 0.73–0.78 (t, *J* = 12 Hz, 4H), 3.35–3.39 (t, *J* = 8 Hz, 4H), 4.75 (s, 4H), 7.20–7.24 (t, *J* = 8 Hz, 1H), 7.28–7.32 (t, *J* = 8 Hz, 2H), 7.40–7.42 (d, *J* = 8 Hz, 2H), 7.46–7.50 (t, *J* = 8 Hz, 2H), 7.59–7.63 (t, *J* = 8 Hz, 1H), 7.83–7.85 (d, *J* = 8 Hz, 2H), 7.88–7.89 (m, 1H), 7.94–7.96 (d, *J* = 8 Hz, 3H), 8.01–8.03 (d, *J* = 8 Hz, 2H), ppm. IR: ν 1461 and 2923 cm⁻¹.

4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)-N,N-bis((2-trimethylsilyloxy)methyl)benzenesulfonamide (34). It was synthesized as **27** starting from **32** and **24**. Yield 65%, oil. ¹H NMR (DMSO-*d*₆, 400 MHz): δ 0.03 (s, 18H), 0.84–0.88 (m, 4H), 3.50–3.54 (m, 4H), 3.78 (s, 6H), 3.86 (s, 3H), 4.79 (s, 4H), 7.10 (s, 2H), 7.18–7.26 (m, 2H), 7.26–7.28 (m, 2H), 7.32–7.35 (m, 2H), 7.56–

7.58 (m, 2H), 7.63 (d, $J = 2.5$ Hz, 1H), 8.02–8.05 ppm (m, 2H). IR ν 1463 and 2922 cm^{-1} .

3-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (35). It was synthesized as **27** starting from **32** and **25**. Yield 61% as an oil. ^1H NMR (DMSO- d_6 , 400 MHz): δ 0.11 (s, 18H), 0.69–0.73 (t, $J = 8$ Hz, 4H), 3.36–3.40 (t, $J = 8$ Hz, 4H), 3.73 (s, 3H), 3.77 (s, 6H), 3.79 (s, 4H), 7.13 (s, 2H), 7.19–7.23 (t, $J = 8$ Hz, 1H), 7.27–7.31 (t, $J = 8$ Hz, 2H), 7.38–7.39 (d, $J = 4$ Hz, 2H), 7.69–7.73 (t, $J = 8$ Hz, 1H), 7.80–7.82 (d, $J = 8$ Hz, 1H), 7.86–7.87 (d, $J = 4$ Hz, 1H), 8.08 (m, 1H), 8.11–8.13 (d, $J = 8$ Hz, 1H), 8.18 (s, 1H) ppm. IR ν 1463 and 2922 cm^{-1} .

2-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (36). It was synthesized as **27** starting from **32** and **26**. Yield 24% as an oil. ^1H NMR (DMSO- d_6 , 400 MHz): δ 0.10 (s, 8H), 0.64–0.68 (t, $J = 8$ Hz, 4H), 3.29–3.33 (t, $J = 8$ Hz, 4H), 3.72 (s, 3H), 3.80 (s, 6H), 4.46 (s, 4H), 7.18–7.19 (m, 3H), 7.21–7.24 (t, $J = 4$ Hz, 1H), 7.28–7.32 (t, $J = 8$ Hz, 2H), 7.37–7.39 (d, $J = 8$ Hz, 2H), 7.48–7.49 (d, $J = 4$ Hz, 1H), 7.67–7.69 (d, $J = 8$ Hz, 1H), 7.71–7.75 (t, $J = 8$ Hz, 1H), 7.82–7.86 (t, $J = 8$ Hz, 1H), 8.12–8.14 (d, $J = 8$ Hz, 1H) ppm. IR ν 1464 and 2919 cm^{-1} .

4-(3-Benzoyl-1H-indol-1-yl)-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (39). It was synthesized as **27** starting from **37** and **24**. Yield 17% as an oil. ^1H NMR (CDCl₃, 400 MHz): δ 0.03 (s, 18H), 0.84–0.88 (t, $J = 8$ Hz, 4H), 1.49–1.53 (t, $J = 8$ Hz, 4H), 4.81 (s, 4H), 7.36–7.43 (m, 2H), 7.48–7.52 (t, $J = 8$ Hz, 2H), 7.54–7.58 (t, $J = 8$ Hz, 2H), 7.64–7.66 (d, $J = 8$ Hz, 2H), 7.76 (s, 1H), 7.86–7.88 (d, $J = 8$ Hz, 2H), 8.09–8.11 (d, $J = 8$ Hz, 2H), 8.48–8.50 (d, $J = 8$ Hz, 1H) ppm. IR: ν 1630 and 2952 cm^{-1} .

4-(3-(3,4,5-Trimethoxybenzoyl)-1H-indol-1-yl)-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (40). It was synthesized as **27** starting from **38** and **24**. Yield 40% as an oil. ^1H NMR (DMSO- d_6 , 400 MHz): δ 0.01 (s, 18H), 0.83–0.87 (m, 4H), 3.48–3.53 (m, 4H), 3.85 (s, 3H), 3.95 (s, 6H), 4.88 (s, 4H), 7.28–7.29 (m, 2H), 7.45–7.52 (m, 2H), 7.72–7.76 (m, 1H), 8.03–8.06 (m, 2H), 8.15–8.18 (m, 2H), 8.39 (s, 1H) and 8.44–8.47 ppm (1H). IR ν 1463 and 2922 cm^{-1} .

3-(3-(3,4,5-Trimethoxybenzoyl)-1H-indol-1-yl)-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (41). It was synthesized as **27** starting from **38** and **24**. Yield 39% as an oil. ^1H NMR (DMSO- d_6 , 400 MHz): δ 0.14 (s, 18H), 0.65 (s, 4H), 3.76 (s, 3H), 3.87 (s, 6H), 4.78 (s, 4H), 7.22 (s, 2H), 7.39 (s, 2H), 7.55 (s, 1H), 7.83–7.85 (m, 1H), 7.96–8.05 (m, 2H), 8.15 (s, 1H), 8.35 (s, 2H) ppm. IR: 1452 and 2892 cm^{-1} .

2-(3-(3,4,5-Trimethoxybenzoyl)-1H-indol-1-yl)-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (42). It was synthesized as **27** starting from **38** and **26**. Yield 61% as an oil. ^1H NMR (DMSO- d_6 , 400 MHz): δ 0.11 (s, 18H), 0.62–0.66 (t, $J = 8$ Hz, 4H), 3.23–3.28 (m, 4H), 3.99–4.15 (m, 4H), 6.98–7.00 (d, $J = 8$ Hz, 1H), 7.22 (s, 2H), 7.27–7.31 (t, $J = 8$ Hz, 1H), 7.34–7.38 (t, $J = 8$ Hz, 1H), 7.65–7.67 (d, $J = 8$ Hz, 1H), 7.79–7.83 (t, $J = 8$ Hz, 1H), 7.87–7.91 (t, $J = 8$ Hz, 1H), 8.19–8.20 (m, 2H), 8.34–8.36 (d, $J = 8$ Hz, 1H) ppm. IR ν 1462 and 2922 cm^{-1} .

General Procedure for the Preparation of Compounds 24–26.

Example: 4-Bromo-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (24). 4-Bromobenzenesulfonamide (1.0 g, 4.24 mmol) in DMF (12 mL) was added dropwise to a suspension of sodium hydride (60% in mineral oil, 408 mg, 9.32 mmol) at 0 °C in DMF (12 mL) under an argon stream. The mixture was allowed to stir at room temperature for 20 min. (2-(Chloromethoxy)ethyl)-trimethylsilane (1.47 g, 8.8 mmol) was added dropwise at 0 °C, and the mixture was stirred at room temperature for 30 min. The reaction was quenched on crushed ice and extracted with ethyl acetate. The organic layer was washed with brine, dried on anhydrous sodium sulfate, and filtered. Removal of the solvent gave pure **24** (2.0 g) that was used without further purification. Yield 98% as an oil. ^1H NMR (CDCl₃, 400 MHz): δ 0.02 (s, 18H), 0.84 (m, 4H), 3.47 (m, 4H), 4.76 (s, 4H), 7.61 (d, $J = 8.5$ Hz, 2H), 7.76 (d, $J = 8.5$ Hz, 2H) ppm. ^{13}C NMR (CDCl₃, 100 MHz): δ 1.32, 17.96, 65.97, 76.49, 127.65, 129.06, 132.17, 140.54 ppm.

3-Bromo-N,N-bis((2-(Trimethylsilyl)ethoxy)methyl)benzenesulfonamide (25). It was synthesized as **24** starting from 3-bromobenzenesulfonamide. Yield 97% as an oil. ^1H NMR (CDCl₃, 400 MHz): δ 0.02 (s, 18H), 0.83–0.87 (t, $J = 8$ Hz, 4H), 3.46–3.50 (t, $J = 8$ Hz, 4H), 4.76 (s, 4H), 7.33–7.37 (t, $J = 8$ Hz, 1H), 7.65–7.67 (d, $J = 8$ Hz, 1H), 7.81–7.83 (d, $J = 8$ Hz, 1H), 8.07 (s, 1H) ppm.

2-Bromo-N,N-bis((2-(Trimethylsilyl)ethoxy)methyl)benzenesulfonamide (26). It was synthesized as **24** starting from 2-bromobenzenesulfonamide. Yield 90% as an oil. ^1H NMR (CDCl₃, 400 MHz): 0.04 (s, 18H), 0.74–0.78 (t, $J = 8$ Hz, 4H), 3.37–3.41 (t, $J = 8$ Hz, 4H), 4.90 (s, 4H), 7.36–7.40 (t, $J = 8$ Hz, 1H), 7.43–7.47 (t, $J = 8$ Hz, 1H), 7.70–7.72 (d, $J = 8$ Hz, 1H), 8.18–8.20 (d, $J = 8$ Hz, 1H) ppm. ^{13}C NMR (CDCl₃, 100 MHz): δ 1.30, 17.90, 65.84, 76.69, 120.57, 127.74, 132.03, 133.70, 135.52, 140.10 ppm.

Molecular Modeling. All the docking experiments were performed on a SuperMicro, Intel Xeon Silver powered machine (64 cores in total) running Ubuntu 20.04 LTS. The crystal structures of hCA I (PDB ID: 7Q0D), hCA II (PDB ID: 5E2R), hCA IX (PDB ID: 5FL4), and hCA XII (PDB ID: 6G7A) were downloaded from the PDB (<https://www.rcsb.org/>) and prepared using Maestro (Schrödinger Release 2022–4: Maestro, Schrödinger, LLC, New York, NY, 2021).⁵⁷ Hydrogen atoms, missing side chains, and missing loops were added; unnecessary side chains, water molecules, and other solvents were removed. The 3D structures of the sulfonamide compounds were protonated at physiological pH and minimized using the OPLS4 force field included in the same software.⁵⁸ AutoDock Vina 1.2.3⁵⁹ was selected as a docking tool owing to its capacity of utilizing the specific zinc-coordination potentials included in the AutoDock4Zn force field.⁶⁰ All prepared proteins were aligned to a chosen reference structure (hCA II, in our case, was used also for numeration of the amino acid residues) using UCSF Chimera,⁶¹ and the docking center was selected by calculating the geometric center of its cocrystallized ligand. AutoDockTools 1.5.7 was used to visually adjust the grid box sizes to the hCA active site. Docking simulations were run using the AutoDock4⁶² scoring function with an exhaustiveness of 32. Prepared proteins and ligands structures were converted to the PDBQT format using OpenBabel 3.0.1^{63,64} while the grid maps generation and the docking process itself were performed in a batch fashion using a custom Python 2.7.3 script. The docking at the colchicine site of tubulin was performed using 3HKD⁶⁵ for derivative **11** and the 1SA0⁶⁶ structure for derivative **15** and **19**. Proteins were prepared as described for the hCAs. Docking computations were carried out with Plants⁶⁷ using the default setting and a binding site of 12 Å. Reported images were generated by PyMol.⁶⁸

Biology. CA Inhibition Screening Assay. An Applied Photophysics stopped-flow instrument was used for assaying the CA-catalyzed CO₂ hydration activity.³⁷ Phenol red (at a concentration of 0.2 mM) was used as an indicator, working at the maximum absorbance of 557 nm, with 20 mM Hepes (pH 7.5) as buffer and 20 mM sodium sulfate (for maintaining constant ionic strength). The initial rates of the CA-catalyzed CO₂ hydration reaction were followed for a period of 10–100 s. The CO₂ concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor, at least six traces of the initial 5–10% of the reaction were used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of the inhibitor (0.1 mM) were prepared in distilled–deionized water, and dilutions up to 0.01 nM were carried out thereafter with distilled–deionized water. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay to allow for the formation of the enzyme–inhibitor complex. The inhibition constants were obtained by nonlinear least-squares methods using the Cheng–Prusoff equation and represent the mean from at least three different determinations. Standard deviations were in the range of ± 5 –10% of the reported K_i values. CA isoforms were recombinant enzymes obtained in house as reported previously.^{69–71} The enzyme concentrations in the assay system were as follows: hCA I, 13.2 nM; hCA II, 8.4 nM; hCA IX, 7.9 nM; and hCA XII, 15.2 nM.

Tubulin Assembly. The reaction mixtures contained 0.8 M monosodium glutamate (pH 6.6 with HCl in a 2 M stock solution), 10 μM tubulin, 4% (v/v) DMSO, and varying concentrations of compound. Following a 15 min preincubation at 30 $^{\circ}\text{C}$, samples were chilled on ice, GTP to 0.4 mM was added, and turbidity development was followed at 350 nm in a temperature-controlled recording spectrophotometer for 20 min at 30 $^{\circ}\text{C}$. The extent of the reaction was measured. Full experimental details were previously described.⁷²

^3H Colchicine-Binding Assay. The reaction mixtures contained 1.0 μM tubulin, 5.0 μM [^3H]colchicine, and 5.0 μM inhibitor and were incubated for 10 min at 37 $^{\circ}\text{C}$. Complete details were described previously.⁷³

Cell Cultures and Cell Viability Assay. Cell lines were obtained from the American Tissue Culture Collection (ATCC), unless specified otherwise. Cells were grown in Dulbecco's modified Eagle's medium (D-MEM) supplemented with 10% fetal bovine serum (FBS) at 37 $^{\circ}\text{C}$ with 5% CO_2 . In all experiments, 300,000 cells were plated in 9 cm^2 dishes and exposed to test compound dissolved in DMSO (0.1% final concentration) at the indicated concentrations. The methodology for the evaluation of the growth of human MCF-7 breast carcinoma, OVCAR-8, and NCI/ADR-RES cells, obtained from the National Cancer Institute drug screening laboratory, was previously described.⁷³ For IC_{50} determinations, OVCAR-8 and NCI/ADR-RES cells were grown in RPMI 1640 medium with 5% FBS, 5% CO_2 atmosphere at 37 $^{\circ}\text{C}$, for 96 h. HCT116, SW480, and SW620 cells were grown in DMEM supplemented with 10% FBS and Pen/Strep (15,070–063, GIBCO, Thermo Fisher Scientific, Waltham, MA, USA). Cell viability was evaluated by sodium 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT)⁷⁴ (HCT116 cells) or 3'-[1-[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene-sulfonic acid hydrate (XTT)⁷⁵ (SW480 and SW620 cells). Briefly, cells (range 10–30 $\times 10^3$ cells/well) were seeded in 96-well microculture plates and then exposed to increasing concentrations of different compounds (range 0–300 μM) for 48 or 72 h. At the end of the treatment, media were removed and incubated at 37 $^{\circ}\text{C}$ in the dark for 4 h in phosphate-buffered saline (PBS) containing 0.2 mg/mL MTT or XTT and PMS (phenazine methosulfate) at a final concentration of 25 μM . Absorbance at 450 nm along with the reference wavelength at 650 nm was measured using a microplate spectrophotometer (Multiskan FC Microplate Photometer, Thermo Scientific, Waltham, MA, USA). The cell growth inhibition rate was calculated utilizing the following formula: inhibition rate (%) = $[\text{control OD} - (\text{sample OD}/\text{control OD})] \times 100$, where control OD is the absorbance of a negative control, and sample OD is the absorbance of the test sample. The IC_{50} values were determined with GraphPad Prism 5 through constructed dose–response curves. Human MDA-MB-231 TNBC cells (ATCC HTB-26) were grown in DMEM supplemented with 10% FCS, while TNBC cells BT-549 (ATCC HTB-122) were grown in RPMI plus 10% FBS and 1 $\mu\text{g}/\text{mL}$ bovine insulin. Cells were kept at low passage, returning to the original frozen stocks every 3–4 months. Hypoxic culture conditions were realized in the presence of 1% O_2 and 5% CO_2 . The different cell lines were seeded 10,000 cells/well in 48-well plates and treated in 1% FBS with increasing concentrations of compound 15 or reference SLC-0111. After 72 h of incubation at 37 $^{\circ}\text{C}$ with 1% O_2 and 5% CO_2 , cells were trypsinized, and cell counting was performed with the MACSQuant analyzer (Miltenyi Biotec).⁷⁶ Potential toxicity on healthy cells was evaluated by treating human primary T lymphocytes from two healthy donors with 30 μM 15 or with a control vehicle (DMSO). Healthy donors' peripheral blood mononuclear cells (PBMCs) were isolated by Lymphoprep (Nycomed) gradient centrifugation. T lymphocytes were negatively selected from PBMCs using magnetic Dynabeads Untouched Human T Cells Kit (Thermo Fisher Scientific) following the manufacturer's instructions. Apoptotic cell death was evaluated using APC Annexin-V Apoptosis Detection Kit with PI (Thermo Fisher Scientific). Briefly, 1.5×10^6 mL T cells were cultured in 48-well plates, untreated or treated with 15 at 30 μM for 72 h. Cells were then stained using annexin-V/APC and propidium iodide according to the manufacturer's instruction. Cell populations were acquired using a FACS Canto II flow cytometer

(BD Biosciences). Flow cytometric analysis was performed using Flow Jo Flow Cytometric Analysis Software. Human chemosensitive HT29 colon cancer cells were purchased from ATCC (Manassas, VA). These cells were cultured in RPMI 1640 medium supplemented with 10% v/v FBS, 1% v/v penicillin–streptomycin, and 1% v/v L-glutamine. Human HT29/DX cells were generated by stepwise selection in medium with an increasing concentration of DOX, as described previously,⁵³ and maintained in culture medium with a final concentration of 200 nM DOX. MDCK and MDCK/P-gp (a gift of Prof. P. Borst, NKI-AVL Institute, Amsterdam, The Netherlands) were grown in DMEM high glucose supplemented with 10% FBS, 1% penicillin, 1% v/v penicillin–streptomycin, and 1% v/v glutamine. All cell lines were authenticated by microsatellite analysis using the PowerPlex kit (Promega Corporation, Madison, WI; last authentication: January 2022). Cells were seeded in 96-well plates. In the first experimental set, cells were incubated for 72 h with DMSO as a solvent or compound 15 at the following concentrations: 0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM , and 10 μM . In the second experimental set, cells were incubated for 72 h with 5 μM DOX alone or with 15 at 1, 10, or 100 nM. Cell viability was evaluated using the WST-1 assay (Sigma-Merck), as per the manufacturer's instructions, using a Packard EL340 microplate reader (Bio-Tek Instruments, Winooski, VT). The absorbance units of the untreated cells were considered 100%; the absorbance units of the other experimental conditions were expressed as a percentage versus the absorbance units of the untreated cells.

Wnt Reporter Assay. Wnt reporter assay was performed as previously described.⁷⁷ HEK293T cells were seeded at 2×10^4 cells/ cm^2 in triplicate in a 24-well plate. The following day, cells were transfected using DreamFect Gold (OZ Biosciences #DG80500) according to the manufacturer's instructions. 25 ng of the TOP reporter vector (M50 Super 8x TOPFlash Addgene #12456) or 25 ng of the FOP control plasmid (M51 Super 8x FOPFlash Addgene #12457) was transfected in each well in combination with 10 ng of TK Renilla (Promega #E2241) and empty vector (pcDNA3.1) up to 100 ng. After 24 h, cells were incubated with starvation media (Opti-MEM reduced serum medium supplemented with 0.5% FBS, 1% penicillin/streptomycin, 1% sodium pyruvate, and 1% nonessential amino acids) for 8 h. After starvation, Wnt/ β -catenin signaling was activated by treating cells with lithium chloride (50 mM) in a starvation medium for 24 h. The following day, cells were treated with increasing concentrations of compound 15 or vehicle (DMSO) for 24 h, and, at the end of the experiment, cells were lysed using Passive Lysis Buffer (Biotium #99912). D-Luciferase (#10101 Biotium) was diluted in the noncommercial luciferase buffer⁷⁸ at a final concentration of 40 $\mu\text{g}/\text{mL}$. Coelenterazine (#S053 Synchem) was diluted in PBS with Ca^{2+} and Mg^{2+} at a final concentration of 0.75 $\mu\text{g}/\text{mL}$. Luminescence was measured using the GloMax Discover Microplate Reader (Promega).

ATPase Activity. The P-gp ATPase activity was measured in membrane vesicles, extracted from HT29/DX or MDCK/P-gp cells treated for 3 h with 1, 10, or 100 nM compound 15, as described previously.⁵³ Cells were washed with Ringer's solution (148.7 mM NaCl, 2.55 mM K_2HPO_4 , 0.45 mM KH_2PO_4 , 1.2 mM MgSO_4 ; pH 7.4), lysed on crushed ice with lysis buffer (10 mM Hepes/Tris, 5 mM EDTA, 5 mM EGTA, 2 mM dithiothreitol; pH 7.4) supplemented with 2 mM phenylmethylsulfonyl fluoride, 1 mM aprotinin, 10 $\mu\text{g}/\text{mL}$ pepstatin, 10 $\mu\text{g}/\text{mL}$ leupeptin, and subjected to nitrogen cavitation at 1200 psi for 20 min. Samples were centrifuged at 300g for 10 min in the precentrifugation buffer (10 mM Tris/HCl, 25 mM sucrose; pH 7.5), overlaid on a sucrose cushion (10 mM Tris/HCl, 35% w/v sucrose, 1 mM EDTA; pH 7.5), and centrifuged at 14,000g for 10 min. The interface was collected, diluted in the centrifugation buffer (10 mM Tris/HCl, 250 mM sucrose; pH 7.5), and subjected to a third centrifugation at 100,000g for 45 min. The vesicle pellet was resuspended in 0.5 mL centrifugation buffer and stored at -80 $^{\circ}\text{C}$ until use, after quantification of the protein content. 1 mg of total protein was immunoprecipitated with the anti-P-gp or anti-MRP1 antibody. 100 μg of each immunopurified protein was incubated for 30 min at 37 $^{\circ}\text{C}$ with 50 μL of the reaction mixture (25

mM Tris/HCl, 3 mM ATP, 50 mM KCl, 2.5 mM MgSO₄, 3 mM dithiothreitol, 0.5 mM EGTA, 2 mM ouabain, 3 mM NaN₃; pH 7.0). The reaction was stopped by adding 0.2 mL of ice-cold stopping buffer (0.2% w/v ammonium molybdate, 1.3% v/v H₂SO₄, 0.9% w/v SDS, 2.3% w/v trichloroacetic acid, and 1% w/v ascorbic acid). After 30 min incubation at room temperature, the absorbance of the phosphate hydrolyzed from ATP was measured at 620 nm, using a Packard EL340 microplate reader. The absorbance was converted into nmoles hydrolyzed phosphate (Pi)/min/mg protein, according to the titration curve previously prepared.

Western Blot. Western blot was performed as previously described.⁷⁹ Cells were washed once in ice-cold PBS and lysed in SDS-urea (50 mM Tris-HCl, 2% SDS, 10% glycerol, 10 mM sodium pyrophosphate, 100 mM NaF, 6 M urea, and 10 mM EDTA). Cell lysates were subjected to SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was blocked, washed, and incubated with primary antibodies at 37 °C overnight [anti- β -catenin (D10A8) XP mAb #8480 (Cell Signaling), anti-cMyc #9402S (Cell Signaling), anticlaved caspase 3 (Asp175) #9661 (Cell Signaling), and anti-PARP #9542S (Cell Signaling)]. After the membrane was washed, it was incubated with secondary antibodies at 37 °C for 30 min. The membrane was washed again with Tris-buffered saline/Tween-20, and the samples were exposed and imaged using the WesternBright ECL solution (#K-12045-DS0 Advansta).

Real-Time PCR. Total mRNA was isolated from cells with TriReagent (#R2050–1–200 Zymo Research), and complementary DNA (cDNA) was synthesized by the Sensifast cDNA synthesis kit (#BIO-65054 Bioline). Quantitative PCR was performed with SensiFast Sybr Lo-Rox Mix (#BIO-94020 Bioline), using an Applied Biosystems ViiA 7 Real-Time PCR System instrument (doi: 10.1038/s41389-019-0175-6) and the following amplification primers:

β -actin forward: CACCCTGAAGTACCCCATCGAG;
 β -actin reverse: GATCTGGGTCATCTTCTCGCCG;
Fgf20 forward: TAGAGGTGTGGACAGTGGTCTC;
Fgf20 reverse: CTTCAAACCTGCTCCCTAAAGATGC;
Sall4 forward: TGCAGCAGTTGGTGGAGAAC;
Sall4 reverse: TCGGTGGCAAATGAGACATTC.

Statistical Analysis. All data in the text and figures are provided as means \pm SD. The results were analyzed by a one-way analysis of variance (ANOVA), Student's *t*-test, and Tukey's test. *p* < 0.05 was considered significant.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c01424>.

Inhibition of tubulin polymerization (IC₅₀ values) by 11, 15, and 19 and references CSA4, 2, and 3: proposed binding mode for derivatives 11, 15, and 19 into the colchicine site on tubulin; effects of 15 on HCT116 cell viability in MTT assay and IC₅₀ value determined by nonlinear regression; total and cleaved PARP and Caspase-3 levels in HCT116 cells upon 72 h treatment with 15; dose-dependent viability and intracellular DOX accumulation of 15-treated HT29 and HT29/DX, MDCK, and MDCK/P-gp cells; rate of ATP hydrolysis in HT29/DX and MDCK/P-gp cells upon treatment with increasing concentrations of 15; and UHPLC chromatograms of compounds 11, 15, and 19 and relative area (%) recorded at 254 nm (PDF)

List of molecular formula string spread sheet for all tested compounds and associated biological data (CSV)
Predicted binding mode of 11, 15, and 19 in hCA I (PDB ID: 7Q0D) (PDB)

hCA II (PDB ID: SE2R) (PDB)

hCA IX (PDB ID: 5FL4) (PDB)

hCA XII (PDB ID: 6G7A) (PDB)

■ AUTHOR INFORMATION

Corresponding Authors

Gianluca Canettieri – Laboratory Affiliated to Istituto Pasteur Italia—Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy; Email: gianluca.canettieri@uniroma1.it

Romano Silvestri – Laboratory Affiliated with the Institute Pasteur Italy—Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Roma 00185, Italy; orcid.org/0000-0003-2489-0178; Email: romano.silvestri@uniroma1.it

Authors

Domiziana Masci – Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Rome 00168, Italy

Michela Puxeddu – Laboratory Affiliated with the Institute Pasteur Italy—Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Roma 00185, Italy

Laura Di Magno – Laboratory Affiliated to Istituto Pasteur Italia—Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy

Michele D'Ambrosio – Laboratory Affiliated with the Institute Pasteur Italy—Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Roma 00185, Italy

Anastasia Parisi – Laboratory Affiliated with the Institute Pasteur Italy—Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Roma 00185, Italy

Marianna Nalli – Laboratory Affiliated with the Institute Pasteur Italy—Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Roma 00185, Italy

Ruoli Bai – Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States

Antonio Coluccia – Laboratory Affiliated with the Institute Pasteur Italy—Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Roma 00185, Italy; orcid.org/0000-0002-7940-8206

Pietro Sciò – Laboratory Affiliated with the Institute Pasteur Italy—Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Roma 00185, Italy

Viviana Orlando – Department of Biology and Biotechnologies “Charles Darwin”, Sapienza University of Rome, Rome 00185, Italy

Sara D'Angelo – Department of Biology and Biotechnologies “Charles Darwin”, Sapienza University of Rome, Rome 00185, Italy

Stefano Biagioni – Department of Biology and Biotechnologies “Charles Darwin”, Sapienza University of Rome, Rome 00185, Italy

Andrea Urbani – Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Rome 00168, Italy

Ernest Hamel – Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States

Alessio Nocentini – Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Università degli Studi di Firenze, Sesto Fiorentino I-50019 Firenze, Italy;

● orcid.org/0000-0003-3342-702X

Serena Filiberti – Experimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy

Marta Turati – Experimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy

Roberto Ronca – Experimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy

Joanna Kopecka – Department of Oncology and Molecular Biotechnology Center “Guido Tarone”, Oncological Pharmacology Unit, Torino 10126, Italy

Chiara Riganti – Department of Oncology and Molecular Biotechnology Center “Guido Tarone”, Oncological Pharmacology Unit, Torino 10126, Italy; ● orcid.org/0000-0001-9787-4836

Cinzia Fionda – Laboratory Affiliated to Istituto Pasteur Italia—Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy

Rosa Bordone – Laboratory Affiliated to Istituto Pasteur Italia—Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy

Giorgia Della Rocca – Laboratory Affiliated to Istituto Pasteur Italia—Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy

Claudiu T. Supuran – Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Università degli Studi di Firenze, Sesto Fiorentino I-50019 Firenze, Italy;

● orcid.org/0000-0003-4262-0323

Giuseppe La Regina – Laboratory Affiliated with the Institute Pasteur Italy—Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Roma 00185, Italy; ● orcid.org/0000-0003-3252-1161

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.jmedchem.3c01424>

Author Contributions

D.M., M.P., and L.D.M. are the first co-authors. D.M., M.D.A., M.N., and M.P., synthesis and spectral data; A.C. and P.S., molecular modeling and drug like; A.N. and C.S., carbonic anhydrase; E.H. and R.B., tubulin; V.O., S.D.A., and S.B., CRC cells; R.R., S.F., M.T., T.N.B.C., and C.F., healthy cells; J.K. and C.R., P-gp; L.D.M., R.B., G.D.R., and G.C., Wnt/ β -catenin pathway; R.S., project coordinator; and G.L.R., supervisor.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors thanks for financial support: AIRC IG 2020 n. 24703 to R.S., AIRC IG 2021 n. 25833 to G.C., AIRC IG 2019 n. 23151 to R.R., and AIRC IG n. 21408 to C.R, MIUR PRIN 2022 2022TPPNTK to G.L.R., 2022L332YR to G.C., Sapienza University of Rome RG11816428A9B4D5 and RM120172A7EAD07C to R.S., RM11916B5598E3C4 and RM12218167FD3A37 to G.L.R., RM12117A85D9076 to M.N. RG12117A61923A6F to G.C., AR1221816C6EE45D for M.D.A., Institute Pasteur Italy—Fondazione Cenci Bolognetti, call 2019 under 45, and call 2020 “Anna Tramontano” to G.C., and Fondazione Umberto Veronesi fellowship to L.D.M. This research was supported in part by the Developmental Therapeutics Program in the Division of Cancer Treatment and Diagnosis of the National Cancer Institute, which includes federal funds under contract no. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

ABBREVIATIONS

AAZ, acetazolamide; CA, carbonic anhydrase; CRC, colorectal cancer; CSA4, combretastatin A-4; DMSO, dimethyl sulfoxide; DOX, doxorubicin; FBS, fetal bovine serum; 5-FU, 5-fluorouracil; PARP, poly(ADP-ribose)polymerase; P-gp, P-glycoprotein; SEM, 2-(trimethylsilyl)ethoxymethyl; TBAF, tetrabutylammonium fluoride; TNBC, triple-negative breast cancer; THF, tetrahydrofuran

REFERENCES

- (1) Supuran, C. T. Carbonic anhydrases. *Bioorg. Med. Chem.* **2013**, *21*, 1377–1378.
- (2) Alterio, V.; Di Fiore, A.; D’Ambrosio, K.; Supuran, C. T.; De Simone, G. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? *Chem. Rev.* **2012**, *112*, 4421–4468.
- (3) De Simone, G.; Di Fiore, A.; Capasso, C.; Supuran, C. T. The zinc coordination pattern in the η -carbonic anhydrase from *Plasmodium falciparum* is different from all other carbonic anhydrase genetic families. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 1385–1389.
- (4) Supuran, C. T.; Scozzafava, A. Carbonic anhydrases as targets for medicinal chemistry. *Bioorg. Med. Chem.* **2007**, *15*, 4336–4350.
- (5) McKenna, R. In *Carbonic anhydrase: mechanism, regulation, links to disease, industrial applications*; Frost, S. C., McKenna, R., Eds.; Springer Sci. Bus. Media: Dordrecht, The Netherlands, 2014.
- (6) Nocentini, A.; Supuran, C. T. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. *Expert Opin. Drug Discovery* **2019**, *14*, 1175–1197.
- (7) Purkerson, J. M.; Schwartz, G. J. The role of carbonic anhydrases in renal physiology. *Kidney Int.* **2007**, *71*, 103–115.
- (8) Tachibana, H.; Gi, M.; Kato, M.; Yamano, S.; Fujioka, M.; Kakehashi, A.; Hirayama, Y.; Koyama, Y.; Tamada, S.; Nakatani, T.; Wanibuchi, H. Carbonic anhydrase 2 is a novel invasion-associated factor in urinary bladder cancers. *Cancer Sci.* **2017**, *108*, 331–337.
- (9) Supuran, C. T.; Scozzafava, A.; Mincione, F. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. *Curr. Pharm. Des.* **2008**, *14*, 649–654.
- (10) Hen, N.; Bialer, M.; Yagen, B.; Maresca, A.; Aggarwal, M.; Robbins, A. H.; McKenna, R.; Scozzafava, A.; Supuran, C. T. Anticonvulsant 4-aminobenzenesulfonamide derivatives with

branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms III, VII, and XIV. *J. Med. Chem.* **2011**, *54*, 3977–3981.

(11) Pollard, A.; Shephard, F.; Freed, J.; Liddell, S.; Chakrabarti, L. Mitochondrial proteomic profiling reveals increased carbonic anhydrase II in aging and neurodegeneration. *Aging* **2016**, *8*, 2425–2436.

(12) Ivanov, S.; Liao, S. Y.; Ivanova, A.; Danilkovitch-Miagkova, A.; Tarasova, N.; Weirich, G.; Merrill, M. J.; Proescholdt, M. A.; Oldfield, E. H.; Lee, J.; Zavada, J.; Waheed, A.; Sly, W.; Lerman, M. L.; Stanbridge, E. J. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. *Am. J. Pathol.* **2001**, *158*, 905–919.

(13) Becker, H. M. Carbonic anhydrase IX and acid transport in cancer. *Br. J. Cancer* **2020**, *122*, 157–167.

(14) Parkkila, S.; Rajaniemi, H.; Parkkila, A. K.; Kivela, J.; Waheed, A.; Pastorekova, S.; Pastorek, J.; Sly, W. S. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 2220–2224.

(15) Ilie, M. I.; Hofman, V.; Ortholan, C.; Ammadi, R. E.; Bonnetaud, C.; Havet, K.; Venissac, N.; Mouroux, J.; Mazure, N. M.; Pousysegur, J.; Hofman, P. Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis. *Int. J. Cancer* **2011**, *128*, 1614–1623.

(16) Yoo, C. W.; Nam, B. H.; Kim, J. Y.; Shin, H. J.; Lim, H.; Lee, S.; Lee, S. K.; Lim, M. C.; Song, Y. J. Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome. *Radiat. Oncol.* **2010**, *5*, 101.

(17) Proescholdt, M. A.; Mayer, C.; Kubitz, M.; Schubert, T.; Liao, S. Y.; Stanbridge, E. J.; Ivanov, S.; Oldfield, E. H.; Brawanski, A.; Merrill, M. J. Expression of hypoxia-inducible carbonic anhydrases in brain tumors. *Neuro-Oncology* **2005**, *7*, 465–475.

(18) Haapasalo, J.; Hilvo, M.; Nordfors, K.; Haapasalo, H.; Parkkila, S.; Hyrskyluoto, A.; Rantala, I.; Waheed, A.; Sly, W. S.; Pastorekova, S.; Pastorek, J.; Parkkila, A. K. Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas. *Neuro-Oncology* **2008**, *10*, 131–138.

(19) Hong, J. H.; Muhammad, E.; Zheng, C.; Hershkovitz, E.; Alkranawi, S.; Loewenthal, N.; Parvari, R.; Muallem, S. Essential role of carbonic anhydrase XII in secretory gland fluid and HCO₃⁻ secretion revealed by disease causing human mutation. *J. Physiol.* **2015**, *593*, 5299–5312.

(20) Viikilä, P.; Kivela, A. J.; Mustonen, H.; Koskensalo, S.; Waheed, A.; Sly, W. S.; Doisy, E. A.; Pastorek, J.; Pastorekova, S.; Parkkila, S.; et al. Carbonic anhydrase enzymes II, VII, IX and XII in colorectal carcinomas. *World J. Gastroenterol.* **2016**, *22*, 8168–8177.

(21) La Regina, G.; Coluccia, A.; Famigliani, V.; Pelliccia, S.; Monti, L.; Vullo, D.; Nuti, E.; Alterio, V.; De Simone, G.; Monti, S. M.; Pan, P.; Parkkila, S.; Supuran, C. T.; Rossello, A.; Silvestri, R. Discovery of 1,1'-biphenyl-4-sulfonamides as a new class of potent and selective carbonic anhydrase XIV inhibitors. *J. Med. Chem.* **2015**, *58*, 8564–8572.

(22) La Regina, G.; Puxeddu, M.; Nalli, M.; Vullo, D.; Gratteri, P.; Supuran, C. T.; Nocentini, A.; Silvestri, R. Discovery of new 1,1'-biphenyl-4-sulfonamides as selective subnanomolar human carbonic anhydrase II inhibitors. *ACS Med. Chem. Lett.* **2020**, *11*, 633–637.

(23) La Regina, G.; Bai, R.; Coluccia, A.; Famigliani, V.; Pelliccia, S.; Passacantilli, S.; Mazzoccoli, C.; Ruggieri, V.; Sisinni, L.; Bolognesi, A.; Rensen, W. M.; Miele, A.; Nalli, M.; Alfonsi, R.; Di Marcotullio, L.; Gulino, A.; Brancale, A.; Novellino, E.; Dondio, G.; Vultaggio, S.; Varasi, M.; Mercurio, C.; Hamel, E.; Lavia, P.; Silvestri, R. New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including Hedgehog-dependent cancer. *J. Med. Chem.* **2014**, *57*, 6531–6552.

(24) La Regina, G.; Bai, R.; Coluccia, A.; Famigliani, V.; Passacantilli, S.; Naccarato, V.; Ortar, G.; Mazzoccoli, C.; Ruggieri, V.; Agriesti, F.; Piccoli, C.; Tataranni, T.; Nalli, M.; Brancale, A.; Vultaggio, S.; Mercurio, C.; Varasi, M.; Saponaro, C.; Sergio, S.; Maffia, M.; Coluccia, A.; Hamel, E.; Silvestri, R. 3-Aroyl-1,4-diarylpyrroles inhibit

chronic myeloid leukemia cell growth through an interaction with tubulin. *ACS Med. Chem. Lett.* **2017**, *8*, 521–526.

(25) De Martino, G.; Edler, M. C.; La Regina, G.; Coluccia, A.; Barbera, M. C.; Barrow, D.; Nicholson, R. I.; Chiosis, G.; Brancale, A.; Hamel, E.; Artico, M.; Silvestri, R. New Arylthioindoles: Potent Inhibitors of Tubulin Polymerization. 2. Structure–Activity Relationships and Molecular Modeling Studies. *J. Med. Chem.* **2006**, *49*, 947–954.

(26) Guo, S.; Zhen, Y.; Guo, M.; Zhang, L.; Zhou, G. Design, synthesis and antiproliferative evaluation of novel sulfanilamide-1,2,3-triazole derivatives as tubulin polymerization inhibitors. *Invest. New Drugs* **2018**, *36*, 1147–1157.

(27) Matsue, T.; Gi, M.; Shiota, M.; Tachibana, H.; Suzuki, S.; Fujioka, M.; Kakehashi, A.; Yamamoto, T.; Kato, M.; Uchida, J.; Wanibuchi, H. The carbonic anhydrase inhibitor acetazolamide inhibits urinary bladder cancers via suppression of β -catenin signaling. *Cancer Sci.* **2022**, *113*, 2642–2653.

(28) McConkey, D. J.; Choi, W.; Marquis, L.; Martin, F.; Williams, M. B.; Shah, J.; Svatek, R.; Das, A.; Adam, L.; Kamat, A.; Siefker-Radtke, A.; Dinney, C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. *Cancer Metastasis Rev.* **2009**, *28*, 335–344.

(29) Di Magno, L.; Di Pastena, F.; Puxeddu, M.; La Regina, G.; Coluccia, A.; Ciogli, A.; Manetto, S.; Maroder, M.; Canettieri, G.; Silvestri, R.; Nalli, M. Sulfonamide inhibitors of β -catenin signaling as anticancer agents with different output on c-MYC. *ChemMedChem* **2020**, *15*, 2264–2268.

(30) Fang, L.; Zhu, Q.; Neuenchwander, M.; Specker, E.; Wulf-Goldenberg, A.; Weis, W. L.; von Kries, J. P.; Birchmeier, W. A small molecule antagonist of the β -catenin/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis. *Cancer Res.* **2016**, *76*, 891–901.

(31) Kopecka, J.; Campia, I.; Jacobs, A.; Frei, A. P.; Ghigo, D.; Wollscheid, B.; Riganti, C. Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. *Oncotarget* **2015**, *6*, 6776–6793.

(32) Kopecka, J.; Rankin, G. M.; Salaroglio, I. C.; Poulsen, S. A.; Riganti, C. P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors. *Oncotarget* **2016**, *7*, 85861–85875.

(33) Tardia, P.; Stefanachi, A.; Niso, M.; Stolf, D. A.; Mangiardi, G. F.; Alberga, D.; Nicolotti, O.; Lattanzi, G.; Carotti, A.; Leonetti, F.; Perrone, R.; Berardi, F.; Azzariti, A.; Colabufo, N. A.; Cellamare, S. Trimethoxybenzanilide-based P-glycoprotein modulators: an interesting case of lipophilicity tuning by intramolecular hydrogen bonding. *J. Med. Chem.* **2014**, *57*, 6403–6418.

(34) Puxeddu, M.; Wu, J.; Bai, R.; D'Ambrosio, M.; Nalli, M.; Coluccia, A.; Manetto, S.; Ciogli, A.; Masci, D.; Urbani, A.; Fionda, C.; Coni, S.; Bordone, R.; Canettieri, G.; Bigogno, C.; Dondio, G.; Hamel, E.; Liu, T.; Silvestri, R.; La Regina, G. Induction of ferroptosis in glioblastoma and ovarian cancers by a new pyrrole tubulin assembly inhibitor. *J. Med. Chem.* **2022**, *65*, 15805–15818.

(35) Artico, M.; Di Santo, R.; Costi, R.; Massa, S.; Retico, A.; Artico, M.; Apuzzo, G.; Simonetti, G.; Strippoli, V. Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazole-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents. *J. Med. Chem.* **1995**, *38*, 4223–4233.

(36) La Regina, G.; Sarkar, T.; Bai, R.; Edler, M. C.; Saletti, R.; Coluccia, A.; Piscitelli, F.; Minelli, L.; Gatti, V.; Mazzoccoli, C.; Palermo, V.; Mazzoni, C.; Falcone, C.; Scovassi, A. I.; Giansanti, V.; Campiglia, P.; Porta, A.; Maresca, B.; Hamel, E.; Brancale, A.; Novellino, E.; Silvestri, R. New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies. *J. Med. Chem.* **2009**, *52*, 7512–7527.

(37) Khalifah, R. G. The Carbon Dioxide Hydration Activity of Carbonic Anhydrase. *J. Biol. Chem.* **1971**, *246*, 2561–2573.

(38) Farzam, K.; Abdullah, M. Acetazolamide. NIH, National Library of Medicine. Last Update: July 10, 2022. <https://www.ncbi.nlm.nih.gov/books/NBK532282/> (accessed Jan 29, 2023).

- (39) Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemist's guide to molecular interactions. *J. Med. Chem.* **2010**, *53*, 5061–5084.
- (40) Arnold, A.; Tronser, M.; Sers, C.; Ahadova, A.; Endris, V.; Mamlouk, S.; Horst, D.; Möbs, M.; Bischoff, P.; Kloor, M.; Bläker, H. The majority of β -catenin mutations in colorectal cancer is homozygous. *BMC Cancer* **2020**, *20*, 1038.
- (41) Korinek, V.; Barker, N.; Morin, P.; van Wichen, D.; de Weger, R.; Kinzler, K.; Vogelstein, B.; Clevers, H. Constitutive transcriptional activation by a β -catenin-Tcf complex in APC $^{-/-}$ colon carcinoma. *Science* **1997**, *275*, 1784–1787.
- (42) Morin, P.; Sparks, A.; Korinek, V.; Barker, N.; Clevers, H.; Vogelstein, B.; Kinzler, K. Activation of β -catenin-Tcf signaling in colon cancer by mutations in β -catenin or APC. *Science* **1997**, *275*, 1787–1790.
- (43) La Regina, G.; Bai, R.; Rensen, W.; Coluccia, A.; Piscitelli, F.; Gatti, V.; Bolognesi, A.; Lavecchia, A.; Granata, I.; Porta, A.; Maresca, B.; Soriani, A.; Iannitto, M. L.; Mariani, M.; Santoni, A.; Brancale, A.; Ferlini, C.; Dondio, G.; Varasi, M.; Mercurio, C.; Hamel, E.; Lavia, P.; Novellino, E.; Silvestri, R. Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability. *J. Med. Chem.* **2011**, *54*, 8394–8406.
- (44) McDonald, P. C.; Chia, S.; Bedard, P. L.; Chu, Q.; Lyle, M.; Tang, L.; Singh, M.; Zhang, Z.; Supuran, C. T.; Renouf, D. J.; Dedhar, S. A Phase I study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. *Am. J. Clin. Oncol.* **2020**, *43*, 484–490.
- (45) Soldani, C.; Scovassi, A. I. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. *Apoptosis* **2002**, *7*, 321–328.
- (46) Crowley, L. C.; Waterhouse, N. J. Detecting cleaved caspase-3 in apoptotic cells by flow cytometry. *Cold Spring Harb. Protoc.* **2016**, *2016* (11), pdb.prot087312.
- (47) Zhang, M.; Du, H.; Wang, L.; Yue, Y.; Zhang, P.; Huang, Z.; Lv, W.; Ma, J.; Shao, Q.; Ma, M.; Liang, X.; Yang, T.; Wang, W.; Zeng, J.; Chen, G.; Wang, X.; Fan, J. Thymoquinone suppresses invasion and metastasis in bladder cancer cells by reversing EMT through the Wnt/ β -catenin signaling pathway. *Chem. Biol. Interact.* **2020**, *320*, 109022.
- (48) Riganti, C.; Kopecka, J.; Panada, E.; Barak, S.; Rubinstein, M. The role of C/EBP- β LIP in multidrug resistance. *J. Natl. Cancer Inst.* **2015**, *107*, djv046.
- (49) Braconi, L.; Teodori, E.; Riganti, C.; Coronello, M.; Nocentini, A.; Bartolucci, G.; Pallecchi, M.; Contino, M.; Manetti, D.; Romanelli, M. N.; Supuran, C. T.; Dei, S. New dual P-glycoprotein (P-gp) and human carbonic anhydrase XII (hCA XII) inhibitors as multidrug resistance (MDR) reversers in cancer cells. *J. Med. Chem.* **2022**, *65*, 14655–14672.
- (50) Gazzano, E.; Chegaev, K.; Rolando, B.; Blangetti, M.; Annaratone, L.; Ghigo, D.; Fruttero, R.; Riganti, C. Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. *Bioorg. Med. Chem.* **2016**, *24*, 967–975.
- (51) Pastan, I.; Gottesman, M. M.; Ueda, K.; Lovelace, E.; Rutherford, A. V.; Willingham, M. C. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 4486–4490.
- (52) Arnason, T.; Harkness, T. Development, maintenance, and reversal of multiple drug resistance: at the crossroads of TFPII, ABC transporters, and HIF1. *Cancers* **2015**, *7*, 2063–2082.
- (53) Kopecka, J.; Salzano, G.; Campia, I.; Lusa, S.; Ghigo, D.; De Rosa, G.; Riganti, C. Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition. *Nanomedicine* **2014**, *10*, 77–87.
- (54) Riganti, C.; Gazzano, E.; Gulino, G. R.; Volante, M.; Ghigo, D.; Kopecka, J. Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. *Cancer Lett.* **2015**, *360*, 219–226.
- (55) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Delivery Rev.* **1997**, *23*, 3–25.
- (56) Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. *J. Med. Chem.* **2002**, *45*, 2615–2623.
- (57) Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. *J. Comput. Aided Mol. Des.* **2013**, *27*, 221–234.
- (58) Lu, C.; Wu, C.; Ghoreishi, D.; Chen, W.; Wang, L.; Damm, W.; Ross, G. A.; Dahlgren, M. K.; Russell, E.; Von Bargen, C. D.; Abel, R.; Friesner, R. A.; Harder, E. D. OPLS4: improving force field accuracy on challenging regimes of chemical space. *J. Chem. Theory Comput.* **2021**, *17*, 4291–4300.
- (59) Eberhardt, J.; Santos-Martins, D.; Tillack, A. F.; Forli, S. AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings. *J. Chem. Inf. Model.* **2021**, *61*, 3891–3898.
- (60) Santos-Martins, D.; Forli, S.; Ramos, M. J.; Olson, A. J. AutoDock4(Zn): an improved AutoDock force field for small-molecule docking to zinc metalloproteins. *J. Chem. Inf. Model.* **2014**, *54*, 2371–2379.
- (61) Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera—a visualization system for exploratory research and analysis. *J. Comput. Chem.* **2004**, *25*, 1605–1612.
- (62) Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. *J. Comput. Chem.* **2009**, *30*, 2785–2791.
- (63) Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A semiempirical free energy force field with charge-based desolvation. *J. Comput. Chem.* **2007**, *28*, 1145–1152.
- (64) O'Boyle, N. M.; Banck, M.; James, C. A.; Morley, C.; Vandermeersch, T.; Hutchison, G. R. Open Babel: an open chemical toolbox. *J. Cheminf.* **2011**, *3*, 33.
- (65) Dorleans, A.; Gigant, B.; Ravelli, R. B. G.; Mailliet, P.; Mikol, V.; Knossow, M. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106*, 13775–13779.
- (66) Ravelli, R. B.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. *Nature* **2004**, *428*, 198–202.
- (67) Korb, O.; Stutzle, T.; Exner, T. E. PLANTS: application of ant colony optimization to structure-based drug design. In *Ant Colony Optimization and Swarm Intelligence, Proceedings of the 5th International Workshop, ANTS*; Dorigo, M.; Gambardella, L. M.; Birattari, M.; Martinoli, A.; Poli, R.; Stutzle, T., Eds.; Lecture Notes in Computer Science, Series 4150; Springer: Berlin, 2006; pp 247–258.
- (68) *The PyMol Molecular Graphics System*, Version 2.0; Schrödinger, LLC: 2015.
- (69) Vitale, R. M.; Alterio, V.; Innocenti, A.; Winum, J. Y.; Monti, S. M.; De Simone, G.; Supuran, C. T. Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-binding, more isoform-selective inhibitors. *J. Med. Chem.* **2009**, *52*, 5990–5998.
- (70) D'Ambrosio, K.; Smaine, F. Z.; Carta, F.; De Simone, G.; Winum, J.-Y.; Supuran, C. T. Development of potent carbonic anhydrase inhibitors incorporating both sulfonamide and sulfamide groups. *J. Med. Chem.* **2012**, *55*, 6776–6783.
- (71) Pacchiano, F.; Carta, F.; McDonald, P. C.; Lou, Y.; Vullo, D.; Scozzafava, A.; Dedhar, S.; Supuran, C. T. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. *J. Med. Chem.* **2011**, *54*, 1896–1902.
- (72) Hamel, E. Evaluation of antimetastatic agents by quantitative comparisons of their effects on the polymerization of purified tubulin. *Cell Biochem. Biophys.* **2003**, *38*, 1–22.

(73) Verdier-Pinard, P.; Lai, J.-Y.; Yoo, H.-D.; Yu, J.; Marquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. *Mol. Pharmacol.* **1998**, *53*, 62–76.

(74) Van Meerloo, J.; Kaspers, G. J. L.; Cloos, J. Cell Sensitivity Assays: The MTT Assay. *Methods Mol. Biol.* **2011**, *731*, 237–245.

(75) Roehm, N. W.; Rodgers, G. H.; Hatfield, S. M.; Glasebrook, A. L. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. *J. Immunol. Methods* **1991**, *142*, 257–265.

(76) Giacomini, A.; Taranto, S.; Rezzola, S.; Matarazzo, S.; Grillo, E.; Bugatti, M.; Scotuzzi, A.; Guerra, J.; Di Trani, M.; Presta, M.; Ronca, R. Inhibition of the FGF/FGFR system induces apoptosis in lung cancer cells via c-myc downregulation and oxidative stress. *Int. J. Mol. Sci.* **2020**, *21*, 9376.

(77) Coluccia, A.; La Regina, G.; Naccarato, V.; Nalli, M.; Orlando, V.; Biagioni, S.; De Angelis, M. L.; Baiocchi, M.; Gautier, C.; Gianni, S.; Di Pastena, F.; Di Magno, L.; Canettieri, G.; Coluccia, A. M. L.; Silvestri, R. Drug design and synthesis of first in class PDZ1 targeting NHERF1 inhibitors as anticancer agents. *ACS Med. Chem. Lett.* **2019**, *10*, 499–503.

(78) Dyer, B. W.; Ferrer, F. A.; Klinedinst, D. K.; Rodriguez, R. A noncommercial dual luciferase enzyme assay system for reporter gene analysis. *Anal. Biochem.* **2000**, *282*, 158–161.

(79) Coni, S.; Bordone, R.; Ivy, D. M.; Yurtsever, Z. N.; Di Magno, L.; D'Amico, R.; Cesaro, B.; Fatica, A.; Belardinilli, F.; Bufalieri, F.; Maroder, M.; De Smaele, E.; Di Marcotullio, L.; Giannini, G.; Agostinelli, E.; Canettieri, G. Combined inhibition of polyamine metabolism and eIF5A hypusination suppresses colorectal cancer growth through a converging effect on MYC translation. *Cancer Lett.* **2023**, *559*, 216120.